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ABSTRACT
LOSS OF SKI EXPRESSION IN TESTICULAR CANCER LEADS TO AN
ENHANCED INVASIVE PHENOTYPE THROUGH BOTH BMP-DEPENDENT
AND BMP-INDEPENDENT PATHWAYS
by Amy N. Nash
The proto-oncogene SKI is a transcription factor and a co-repressor of the TGFβ
superfamily, including TGFβ and BMP. However, additional data suggests that SKI may
function as a tumor suppressor in some cell types. The TGFβ superfamily has been
implicated in cancer progression and germ cell migration. Testicular cancer afflicts men
during their peak reproductive years and is the most common cancer among men of this
age group. Cisplatin-based chemotherapy is the standard treatment for testicular cancer.
This treatment can lead to undesirable side effects, including infertility. We have shown
that SKI expression is decreased in testicular germ cell tumors compared to normal
testis. The hypothesis of this work is that decreased SKI expression promotes testicular
cancer progression by allowing unregulated TGFβ superfamily signaling, conferring an
increased ability of testicular cancer cells to invade and metastasize. To test the effects
of decreased SKI in testicular cancer, we used a human embryonal carcinoma cell line,
NCCIT. We found that transient SKI-knockdown confers an increased ability to migrate
and invade, but does not affect proliferation, in NCCIT cells. Forced overexpression of
SKI in NCCIT cells resulted in decreased migration and invasion compared to control
cells. We next investigated whether TGFβ or BMP enhanced the invasive phenotype of
stable SKI-knockdown NCCIT cells. NCCIT cells stably transfected with nonspecific
shRNA were used as a control. Addition of TGFβ or TGFβ blocking antibody had no
effect on the migration of either SKI-knockdown cells or control cells. Addition of BMP4
enhanced migration in SKI-deficient NCCIT cells but had no effect on control cells.
Treatment with noggin, a BMP inhibitor, reduced the migration of SKI-deficient NCCIT
cells back to the level of control cells. These data imply that in NCCIT cells with
decreased SKI expression, the BMP pathway, but not the TGFβ pathway, promotes
migration. Microarray analysis was performed to identify downstream targets of SKI that
may be involved in cellular invasion. CXCR4 expression was increased in SKIknockdown cells compared to control cells, but CXCR4 expression was not affected by
treatment with BMP. Signaling partners CXCR4 and SDF1 have been implicated in
germ cell migration and cancer metastasis. Addition of SDF1 enhanced the invasive
potential of SKI-deficient cells but had no effect on control cells. Addition of AMD3100, a
potent and specific inhibitor of CXCR4, blocked the effects seen with SDF1. These data,
taken together with the BMP data, imply that decreased SKI expression in NCCIT cells
leads to enhanced invasion through both BMP-dependent and BMP-independent
mechanisms. This research provides insight into the mechanism behind testicular
cancer metastasis, and it identifies the BMP signaling pathway and CXCR4/SDF1 as
potential targets for the development of new therapies to treat patients with metastatic
testicular cancer.
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CHAPTER I
INTRODUCTION

Testicular cancer is the most common cancer in American males between
the ages of 18 and 35; however, the molecular mechanisms involved in the
development and progression of testicular cancer are poorly understood. In
recent decades, the incidence of testicular germ cell tumors (TGCTs) has
increased annually at a rate of 3 - 6 percent in Caucasian populations (Ulbright,
1993). The precursor lesions to testicular cancer, termed intratubular germ cell
neoplasia (ITGCN), are thought to arise from primitive germ cells that have
evaded normal differentiation. There are three categories of testicular germ cell
tumors; Type II is the most prevalent type and, therefore, the most widely studied
and will be the main focus of this thesis.
Cancer is a multi-step disease, typically involving alterations in multiple
signaling pathways that eventually lead to cellular transformation. Several genes
have been identified that may be involved in the development and progression of
testicular cancer. However, very few studies have been performed to identify the
mechanism by which these genes promote testicular tumorigenesis.
The proto-oncogene SKI is a transcription factor that can function as a corepressor of the transforming growth factor β (TGFβ) superfamily, including
TGFβ and bone morphogenetic protein (BMP), by binding to SMADs, the
downstream signaling molecules of TGFβ and BMP. The TGFβ superfamily has
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been implicated in cancer growth and metastasis as well as germ cell migration
during development, making them of particular interest in testicular cancer
research. The role of the TGFβ superfamily in cancer is complicated, with
several studies suggesting that TGFβ and BMP may have both tumor suppressor
and tumor promoting functions, which may depend on both cell type and the
stage of cancer progression. Similarly, the role of SKI in cancer is still
incompletely defined and may also be tissue-dependent. Some tumors express
high levels of SKI, however, loss of SKI function has been linked to
tumorigenesis in mice heterozygous for a null mutation in the SKI gene,
suggesting SKI may also function as a tumor suppressor.

Purpose of the Research
The objective of the following body of research is to determine the role
that SKI, which we have found to be decreased in testicular tumor samples
compared to normal testis, plays in testicular cancer. SKI was originally
identified as an oncogene based on its ability to transform avian fibroblasts
(Stavnezer 1981, Colmenares 1989); however, other data has provided evidence
that SKI may have tumor suppressor activities (Shinagawa 2001). The purpose
of the following research is 1) to identify the role of SKI in testicular cancer
progression using biological assays; 2) to determine how upstream signals from
the TGFβ superfamily contribute to the effects of decreased SKI in testicular
cancer; and 3) to identify downstream target genes of SKI that may also
contribute to testicular cancer progression.
2

Significance of the Research
The data presented in this text addresses an area that is lacking in
testicular cancer research by studying the mechanism by which SKI contributes
to the progression of testicular cancer. Furthermore, this research has been
focused on testicular cancer metastasis, an area of testicular cancer that has not
been widely researched. The TGFβ superfamily and SKI have previously been
reported to play conflicting roles in tumorigenesis, apparently depending on the
stage of cancer progression and tissue type; thus, we have sought to define the
specific role that SKI and TGFβ superfamily members play in testicular
tumorigenesis.
This research is significant, not only because it fills a gap in the research,
but also because it will allow a better understanding of testicular cancer
progression. This has been accomplished by investigating SKI and its potential
role as a tumor suppressor of testicular cancer and also by considering the
upstream and downstream signals of SKI that contribute to the overall
mechanism of testicular cancer progression. By providing further insight into
testicular cancer progression, this research may contribute to the development of
more efficient treatments that better preserve male fertility and provide a better
quality of life for patients afflicted with the disease.
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CHAPTER II
LITERATURE REVIEW

Male Germ Cell Development
Very early in mammalian embryonic development, a distinct cell
population arises that has the ability to transmit genetic information from one
generation to the next. These pluripotent cells are primordial germ cells (PGCs),
the fetal precursors to sperm and oocytes, and they are derived from the
proximal epiblasts in response to signals from the extraembryonic ectoderm
(Lawson, et al., 1999; Lawson and Hage, 1994). In the mouse, the specification
of a population of about 45 cells to the germ cell lineage occurs at approximately
embryonic day 7.2; at this time the cell cluster is located in the extraembryonic
mesoderm (Lawson and Hage, 1994). Lawson, et. al. (1999) showed that BMP4,
secreted first from the extraembryonic ectoderm, and later from the
extraembryonic mesoderm, is required for the allocation of the PGC population.
BMP8b is also expressed by the extraembryonic ectoderm, and appears to act
synergistically with BMP4 in the generation of PGCs (Ying, et al., 2000; Ying, et
al., 2001). These cells can be identified by staining for alkaline phosphatase,
which continues to be expressed in these cells during their migratory phase
(Ginsburg, et al., 1990).
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Primordial Germ Cell Migration
During embryonic development, PGCs migrate through the primitive
streak, into the allantois, and then enter the embryonic endoderm, which gives
rise to the hindgut (Anderson, et al., 2000). In the mouse, PGCs migrate through
the hindgut and come to rest in the genital ridge at around embryonic day 11.5
(Anderson, et al., 2000). The migration of the PGCs is dependent upon
interaction with the extracellular matrix (ECM) and specific signals secreted from
the genital ridge. There are several factors associated with the ECM that
influence PCG migration. Fibronectin, an adhesive glycoprotein found in the
ECM, stimulates the migration of PGCs from the hindgut (Ffrench-Constant, et al.,
1991). In the mouse, PGCs lacking β1-integrin, which is involved in cell-ECM
attachment and cell migration, have a reduced ability to colonize the gonad
(Anderson, et al., 1999). During migration, PCGs associate with one another via
cytoplasmic processes. E-cadherin appears to play a role in this connection as it
is upregulated in PGCs when they are leaving the hindgut, and blocking Ecadherin prevented PGC aggregation by preventing their formation of tight
clusters in the genital ridges in vitro (Bendel-Stenzel, et al., 2000). The genital
ridge also secretes factors that influence the direction of PGC migration in vitro,
and TGFβ has been shown to act as a chemoattractant of PGCs in culture,
indicating that it may be one of the factors secreted by the genital ridge (Godin
and Wylie, 1991). The ligand stem cell factor (SCF) and its receptor, c-kit, are
required for PGC survival, migration, and colonization of the hindgut (Besmer, et
al., 1993; Buehr and McLaren, 1993). PGCs express c-kit, and cells of the
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hindgut express SCF (Besmer, et al., 1993). Signaling partners, stromal derived
factor-1 (SDF1) and its receptor, CXCR4, are also required for PGC migration
and survival (Molyneaux, et al., 2003; Stebler, et al., 2004). Migrating PGCs
express CXCR4, and SDF is expressed in the genital ridges (Molyneaux, et al.,
2003). PGCs with mutations in CXCR4 do not colonize the gonad normally
(Stebler, et al., 2004). BMP may also be involved in regulating PGC motility.
PGCs express BMP receptors, and BMP4 increased PGC numbers, while noggin,
a BMP inhibitor, reduced PGC numbers and slowed their migration. Furthermore,
BMPs induced, and noggin suppressed, the expression of SCF in the genital
ridges (Dudley, et al., 2007).

Overview of Spermatogenesis
Once the PGCs enter the genital ridges, they are no longer migratory, and
they are termed gonocytes. Before birth, the gonocytes undergo a few rounds of
mitosis before entering a period of mitotic arrest as prospermatogonia (McLaren,
2003). Spermatogenesis begins at puberty with type A spermatogonia, which
are capable of self-renewal to maintain the germ cell population throughout life.
These cells divide asymmetrically to form type A and type B spermatogonia, the
precursors of the spermatocytes. Type B spermatogonia undergo differentiation
to form primary spermatocytes. Primary spermatocytes enter meiosis I, followed
by spermatocytes undergoing meiosis II to form spermatids (Figure 2.1).
Spermatids then undergo a differentiation process to form mature spermatozoa.
Spermatogenesis is a complicated process that is dependent on specific signals,
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many of which come from Sertoli cells, which provide nutrients and growth
factors to the maturing germ cells (Puglisi, et al., 2004).

Intratubular Germ Cell Neoplasia
While there are distinct groups of testicular cancer with histological
differences, all are believed to be of germ cell origin (Figure 2.1). TGCTs arise
from precursor lesions, known as intratubular germ cell neoplasia (ITGCN) (also
referred to as carcinoma in situ), which are thought to arise from primitive germ
cells that have evaded normal differentiation (Chaganti and Houldsworth, 2000;
Oosterhuis and Looijenga, 2005). ITGCNs, PGCs, and gonocytes have similar
morphologies and some similar patterns of gene expression, including positive
staining for alkaline phosphatase and c-kit expression (Kristensen, et al., 2008).

Testicular Germ Cell Tumor Classifications
Testicular germ cell tumors (TGCTs) have been divided into three
classifications based on epidemiology, their histology, and the age group in
which they occur: Type I – teratomas and yolk sac tumors of newborns and
infants; Type II - seminomatous and non-seminomatous tumors of adolescents
and young adults; and Type III – spermatocytic seminomas of the elderly
(Oosterhuis and Looijenga, 2005). Of these three groups, Type II TGCTs are the
most common and account for approximately 60% of malignancies diagnosed in
men between the ages of 20 – 40 years old (Oosterhuis and Looijenga, 2005;
Ulbright, 1993), also making testicular cancer the most prevalent cancer among
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men of this age group (Chaganti and Houldsworth, 2000). Type I pediatric GCTs
are rarer, constituting about 3% of childhood tumors (Bussey, et al., 1999). In
addition to the testis, type I GCTs can be found in sacrocoxygeal region, head
and neck, and midline of the brain (Looijenga, et al., 2007). Type III TGCTs are
the rarest type, occurring predominantly as benign tumors in males over 50 years
of age (Oosterhuis and Looijenga, 2005). Type III tumors are found primarily in
the testis and rarely metastasize (Looijenga, et al., 2007).
Type II TGCTs consist of seminomas and embryonal carcinomas (also referred
to as nonseminomas) (Figure 2.1). Of these seminomas are the most common
type, comprising about 50% of TGCT (Bahrami, et al., 2007). Seminomas are
rarely seen in pre-pubertal males; they most typically occur in men between the
ages of 34 and 45 (Bahrami, et al., 2007). Seminomas are morphologically
similar to spermatogonial germ cells and generally respond very well to radiation
and chemotherapy (Chaganti and Houldsworth, 2000). Embryonal carcinomas
also encompass tumor types with varying degrees of differentiation, including
teratomas, yolk sack tumors, and choriocarcinomas. Embryonal carcinomas
occur most frequently in men between the ages of 25 and 35 (Bahrami, et al.,
2007). Embryonal carcinomas are comprised of undifferentiated pluripotent stem
cells (Looijenga and Oosterhuis, 1999). Yolk sac tumors and choriocarcinomas
exhibit extraembryonic differentiation patterns (Chaganti and Houldsworth, 2000).
Teratomas display the most complete differentiation and are comprised of a
variety of somatic tissues (Chaganti and Houldsworth, 2000).
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Figure 2.1. Normal germ cell development vs. germ cell tumorigenesis. Normal
germ cell development (left) begins during embryogenesis with primordial germ cells,
which are allocated in the extraembryonic mesoderm and migrate to the genital ridge,
where they are termed gonocytes. Gonocytes undergo a few rounds of mitosis and then
enter mitotic arrest as prospermatogonia before birth. These cells divide asymmetrically
to form type A and type B spermatogonia.
Type B spermatogonia undergo
differentiation, forming primary spermatocytes. Primary spermatocytes enter meiosis I,
and then spermatocytes undergo meiosis II, forming spermatids. Spermatids undergo a
differentiation process to form spermatozoa. Testicular tumorigenesis (right) is thought
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to begin during embryonic development with the transformation with a primitive germ cell,
possibly the primordial germ cell or the gonocyte. Testicular germ cell tumors arise
from intratubular germ cell neoplasia, most commonly during peak reproductive years.
Testicular germ cell tumors consist of seminomas and embryonal carcinomas.
Embryonal carcinomas also encompass tumors with various levels of differentiation,
including teratomas, yolk sac tumors, and choriocarcinomas (adapted from Kristensen,
et al., 2008).
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Risk Factors Associated with Testicular Cancer
There are several risk factors associated with the development of TGCTs,
including both environmental and genetic influences. Testicular cancer generally
occurs at an earlier stage of life than many other types of cancer, thus it is
thought that tumorigenesis may begin during fetal life. It has been proposed that
hormone levels in utero may have some effect on the development of TGCTs.
TGCTs are much more common in Caucasian men than black men, and it has
been suggested that this may be due to higher levels of testosterone during
pregnancy in black women compared to Caucasian women (Looijenga and
Oosterhuis, 1999). There appears to be a genetic component to the
development of TGCTs. TGCT patients with an affected family member
generally develop TGCTs at a younger age and are more likely to have bilateral
disease (Looijenga and Oosterhuis, 1999). Skakkebaek et. al. (2001) proposed
a theory of testicular dysgenesis syndrome, which includes embryonic exposure
to endogenous or environmental factors that affect gonadal development. Risk
factors associated with testicular dysgenesis syndrome and the development of
testicular cancer include cryptorchidism, poor semen quality, Klinefelter’s
syndrome, prior history of a GCT, and family history of GCTs (Chaganti and
Houldsworth, 2000; Oosterhuis and Looijenga, 2005; Skakkebaek, 2004).

Molecular basis of testicular cancer
Most TGCTs display a high degree of aneuploidy. Although various
regions of chromosomal imbalance have been linked to the development of
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testicular germ cell tumors (TGCTs) using microarray and FISH analysis (Korkola,
et al., 2006; McIntyre, et al., 2004; Summersgill, et al., 2001; Zahn, et al., 2006),
little is known about how these chromosomal regions contribute to tumorigenesis
in male germ cells. The most common chromosomal aberration associated with
TGCTs is the occurrence of isochromosome 12p (Chaganti and Houldsworth,
2000; Summersgill, et al., 2001). However, various other chromosomal
alterations are correlated with TGCTs (McIntyre, et al., 2004), including a
frequently observed deletion in the short arm of chromosome 1, where the SKI
gene is located. Chromosome location 1p36 often contains deletions in
testicular cancer samples and is a candidate region for tumor suppressor genes
of testicular cancer (Zahn, et al., 2006). While several studies have looked at
expression profiles in TGCTs in order to identify possible oncogenes and tumor
suppressors involved in testicular cancer, the field is lacking in studies of the
mechanisms of particular genes to discover the specific role they might play in
testicular tumorigenesis. However, the following review of the literature provides
a brief discussion of genes that have been more thoroughly investigated in
testicular cancer research and have been presented as potential tumor
suppressor genes and oncogenes based primarily on their expression pattern
and previously known functions.

OCT3/4
OCT3/4 is a transcription factor that functions to maintain pluripotency and
promotes survival in embryonic stem cells and primordial germ cells (Gidekel, et
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al., 2003; Nichols, 1998; Pesce and Scholer, 2001). OCT3/4 is expressed in
PGCs of the human testis, and its expression gradually decreases with
differentiation into spermatogonia (Rajpert-De Meyts, et al., 2004). This gene is
expressed in germ cell tumors with greater differentiation potential, such as
seminomas and embryonal carcinomas, and has been identified through
immunohistochemistry and microarray studies as a diagnostic marker for ITGCN
(Almstrup, et al., 2007; Cheng, et al., 2007; Oosterhuis and Looijenga, 2005).
While OCT3/4 is useful as a marker for both ITGCN and for identifying metastatic
tumors of unknown origin, it is unknown whether OCT3/4 plays a causal role in
testicular cancer or if it merely reflects the origin and developmental potential of
TGCTs.

CCND2
Nearly all invasive type II TGCTs are positive for overexpression of
chromosome 12p, most commonly due to the presence of one or more copies of
isochromosome 12p (Oosterhuis and Looijenga, 2005). This makes the 12p
region popular for studying potential oncogenes of testicular cancer. One such
gene is cyclin D2 (CCND2), which maps to 12p13, and has been shown through
both immunohistochemistry and RNA studies to be overexpressed in ITGCN and
in most TGCTs (Bartkova, et al., 1999; Houldsworth, et al., 1997; Schmidt and
Fan, 2001). Houldsworth, et. al. (1997) found that CCND2 mRNA and protein
were deregulated in a panel of germ cell tumor (GCT) cell lines and was
aberrantly expressed in all ITGCN studied. Furthermore, CCND2 was more
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highly expressed in GCTs with a less differentiated phenotype. CCND2 was
present in all ITGCNs but was not expressed in normal germ cells. These data
suggest that CCND2 overexpression is an early event in male germ cell
tumorigenesis. It has been suggested that increased expression of CCND2 may
promote cell cycle progression by driving the cell through the G1 checkpoint,
which may confer genomic instability (Houldsworth, et al., 1997).

c-KIT/SCF
The aberrant expression of chromosome 12p due to isochromosome 12p
in TGCTs can result in an under-representation of chromosome 12q, making
chromosome 12q a candidate region for tumor suppressor genes. Murty et. al.
(1992) evaluated 45 TGCT DNA samples with allelic loss at 12q and identified a
high frequency of loss of heterozygosity at 12q13 and 12q22. This group
identified stem cell factor (SCF, also known as MGF), a ligand signaling partner
for KIT, to be located within these chromosomal regions. KIT is expressed in the
primordial germ cells (PGC) during embryogenesis and in proliferating
spermatogonia in the post-natal and adult testis; SCF is secreted from Sertoli
cells (Devouassoux-Shisheboran, et al., 2003). KIT and SCF are regulators of
spermatogenesis; they are involved in PGC migration, cell adhesion, proliferation,
and cell survival (Devouassoux-Shisheboran, et al., 2003). In addition to
decreased expression of SCF, KIT has also been shown to be over-expressed in
some types of TGCTs, especially seminomas (Looijenga, et al., 2003). McIntyre
et. al. (2004) identified an amplification of 4q12, the region in which KIT is
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encoded, and other activating mutations of KIT have been identified (Kemmer, et
al., 2004; Looijenga, et al., 2003; Sakuma, et al., 2003). These activating
mutations have primarily been observed in seminomas as well as ITGCNs and
are absent in non-seminomas (Devouassoux-Shisheboran, et al., 2003; Kemmer,
et al., 2004). KIT and SCF are known to play important roles in spermatogenesis;
however, their function in TGC tumorigenesis has not been fully investigated.

Rb
Another potential tumor suppressor gene of testicular cancer is
retinoblastoma (Rb). While the more differentiated cells of teratocarcinomas and
mixed tumors retain some expression of Rb, Rb mRNA and protein expression is
undetectable in undifferentiated TGCTs, however no mutations in Rb have been
observed at the DNA level (Strohmeyer, et al., 1991). Rb is expressed during
adult male spermatogenesis, but its expression is absent in PGCs, the precursor
cells for TGCTs, and it is also absent in ITGCNs and most seminomas and
embryonal carcinomas (Bartkova, et al., 2003). Since no mutations have been
detected in the DNA sequence of Rb, Bartkova et. al. (2003) suggested that the
lack of expression of Rb in TGCTs may be a reflection of its developmental
control and the cell of origin for TGCTs rather than a tumorigenesis promoting
event.
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GDF3
GDF3 is another candidate oncogene for testicular cancer as it has been
shown to be overexpressed specifically in embryonal carcinomas (Caricasole, et
al., 1998; Clark, et al., 2004; Korkola, et al., 2006; Skotheim, et al., 2005). GDF3
is a TGFβ superfamily member with stem cell specific expression (Caricasole, et
al., 1998). GDF3 expression is low in seminomas but is abundantly expressed in
non-seminomas, especially within embryonal carcinomas and yolk sac
components of tumors. Interestingly, GDF3 maps to the short arm of human
chromosome 12, which, as previously mentioned, is regularly overexpressed in
TGCTs (Caricasole, et al., 1998).
While all TGCTs are thought to arise from a common precursor, ITGCN,
the different tumor types appear to differ in their gene expression profiles. This
would suggest that different types of mutations may predispose the ITGCN
toward the development of a seminomatous tumor over an embryonal carcinoma
or vice versa. Over-representation of chromosome 12p occurs in most ITGCN
and is also common to the various types of TGCTs, further indicating that this
may be a very early event in testicular germ cell tumorigenesis. KIT, on the other
hand, seems to be overexpressed primarily in seminomas and ITGCNs, while
GDF3 is overexpressed in embryonal carcinomas.
Through various other expression based profiles, several other genes
have been identified as possible tumor suppressors or oncogenes of testicular
cancer (Korkola, et al., 2006; McIntyre, et al., 2004; Oosterhuis and Looijenga,
2005; Rodriguez, et al., 2003; Skotheim, et al., 2005; Sugimura, et al., 2004).
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These genes have primarily been identified based on differential expression, and
mutations have been identified in some. However, there is a lack of research
investigating the mechanism by which possible tumor suppressor and oncogenes
may contribute to testicular tumorigenesis.

Treatment for Testicular Cancer
In 1970, metastatic TGCTs claimed the lives of 95 percent of men afflicted,
however, cisplatin-based combination chemotherapy is effective in ablating
TGCTs in more than 80 percent of men with metastatic germ cell tumors
(Masters and Koberle, 2003). The TNM staging system is the most commonly
used method for determining the clinical stage of a testicular germ cell tumor
(AJCC). This system takes into account the size of the primary tumor (T),
involvement of pelvic and abdominal lymph nodes (N), and metastasis (M) of the
cancer to distant sites (Table 2.1). Additionally, the patient’s serum (S) marker
levels are considered. Men with stage I disease have tumors that are confined to
the testis with no evidence of metastasis. A diagnosis of stage II involves
metastasis to the lymph nodes in the abdomen or pelvis, and stage III refers to
cancer that has spread to more distant lymph nodes in the chest, lungs, liver or
brain. High blood marker levels may also result in the diagnosis of stage III. The
serum markers that are evaluated for TNM staging include lactate
dehydrogenase, human chorionic gonadotropin, and alpha-fetoprotein (AJCC).
The standard treatment for TGCTs is combination chemotherapy, containing
bleomycin, etoposide, and cisplatin, followed by surgical resection of the
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remaining tumor (Dearnaley, et al., 2001; Droz and Rivoire, 2001). Stage I
TGCTs, those that are confined to the testis at the time of diagnosis, can usually
be cured surgically (Masters and Koberle, 2003). However, the more
differentiated teratomas are more resistant to chemotherapy (Masters and
Koberle, 2003).
TGCTs are more sensitive to chemotherapy than other types of cancer.
This sensitivity to cisplatin-based chemotherapy may be due to defective DNA
repair mechanisms. TGCTs have been shown to be deficient in nucleotide
excision repair (NER). Specifically they have decreased levels of some NER
proteins, including XPA and ERCC1-XPF proteins, and adding these proteins to
testis tumor extracts restored NER activity to normal levels (Koberle, et al., 1999).
However, forcing the expression of XPA in human testis tumors cells did not
confer an increased resistance to cisplatin (Koberle, et al., 2008), indicating that
other genes, and possibly other DNA repair pathways, are likely involved in
cisplatin sensitivity seen in TGCTs.
While cisplatin-based chemotherapy has proven to be exceedingly successful in
the treatment of patients with testicular germ cell tumors, patients who relapse
after treatment with cisplatin-based chemotherapy have a poor prognosis.
Patients with metastases, especially those with late relapse disease, defined as
tumor recurrence more than two years after successful treatment without the
presence of a contralateral tumor, have a worse prognosis (Sharp, et al., 2008).
The tumors in patients with late relapse are more resistant to chemotherapy
(Sharp, et al., 2008). About ten percent of testicular cancer patients are either
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unresponsive to chemotherapy or relapse after treatment (Mayer, et al., 2003).
These patients are typically treated with intensive chemotherapy, surgical
resection, and, possibly, radiotherapy (Dearnaley, et al., 2001). This more
extensive treatment is effective in about 30% of patients (Dearnaley, et al., 2001).
Though the treatments for testicular cancer described above are highly
effective, they are not without side-effects. The more common side effects of
chemotherapy, also seen in treatment of testicular cancer, include nausea,
vomiting, alopecia, fatigue, neutropenia, and sepsis. Lung toxicity is also of
concern because of the use of bleomycin (Dearnaley, et al., 2001). Testicular
cancer most commonly afflicts men during their peak reproductive years.
Therefore, infertility is an obvious area of concern in the treatment of TGCTs
because chemotherapy frequently results in azoospermia. This is reversible in
70-80% of patients, and patients are usually counseled about the option of
storing sperm (Dearnaley, et al., 2001). However, the potential of treatment for
testicular cancer resulting in infertility is still a major issue when considering
quality of life for patients after treatment.
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Table 2.1. TNM Staging System for Testicular Germ Cell Tumors
Primary Tumor (T) Categories:
T0

No evidence of cancer

Tis

Intratubular germ cell neoplasia (Carcinoma in situ); not invasive

T1

Tumor spread to the membrane surrounding the testis

T2

Tumor limited to testis with vascular/lymphatic invasion

T3

Invasion of the spermatic cord with/without vascular/lymphatic invasion

T4

Invasion of the scrotum with/without vascular/lymphatic invasion

Regional Lymph Nodes (N) Categories:
N0

No cancer cells present in lymph nodes

N1

Metastases with lymph node mass(es) ≤ 2cm

N2

Metastases with lymph node mass(es) ˃ 2cm, but < 5cm

N3

Metastases with lymph node mass(es) ˃ 5cm

Metastasis (M) Categories:
M0

No distant metastasis

M1

Distant metastasis present

M1a

Metastasis to lungs or lymph nodes beyond the abdomen and pelvis

M1b

Metastasis to more distant organs, such as the lung and brain

Serum (S) Marker Levels Categories:
S0

Serum marker levels are normal

S1

Serum markers are slightly elevated

S2

Moderate increase in serum markers

S3

Marker levels are very high
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Testicular cancer metastasis
Approximately 70 percent of testicular germ cell tumors metastasize, with
the most frequent site of metastasis being the retroperitoneal lymph nodes
(Jones, et al., 2006). In non-seminomatous tumors, metastases are more likely
to occur in the lungs, liver, and brain (Dearnaley, et al., 2001). TGCTs are also
less commonly found in the thymus and the pineal gland; it has been questioned
whether TGCTs arising in these areas are due to metastases or if they are
derived from PGCs that failed to complete their migration during embryonic
development (Chaganti and Houldsworth, 2000). Another hypothesis suggested
for the presence of TGCTs located in the mediastinal region is the reverse
migration of early stage TGCTs to these locations; this hypothesis is supported
by data showing that many of the chromosomal aberrations seen in TGCTs of
the gonad, including overrepresentation of chromosome 12p, were also present
in TGCTs located in the mediastinal region (Chaganti, et al., 1994).
Very few studies have been published on genes involved in TGCT
metastasis. SDF1 (also known as CXCL12) and CXCR4 signaling partners
appear to play a role in the pathology of TGCT metastasis (Gilbert, et al., 2009).
CXCR4 and SDF1 belong to the CXC subgroup of a family of chemokines and
their receptors (Vandercappellen, et al., 2008); this group is further divided based
on the presence of an ELR (glutamic acid-leucine-arginine) motif; SDF1 lacks the
ELR motif and binds to receptors, CXCR4 and CXCR7 (Vandercappellen, et al.,
2008). Chemokines and their receptors function in regulating the migration of
cells to a particular destination (Zlotnik, 2008). SDF1 is angiogenic and has been
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shown to be involved in cancer metastasis (Vandercappellen, et al., 2008; Zlotnik,
2008).
SDF1 and CXCR4 have been shown to be involved in PGC migration in
the mouse and zebrafish (Doitsidou, et al., 2002; Molyneaux, et al., 2003). PGCs
express CXCR4, the receptor for the SDF1 ligand, and migrate towards regions
where SDF1 is expressed, including the genital ridge, the final destination of the
PGCs (Doitsidou, et al., 2002; Molyneaux, et al., 2003). Gilbert, et. al. (2009)
have presented data showing that SDF1 is expressed in adult human Sertoli cells,
and CXCR4 is expressed in germ cells, with the exception of mature sperm.
Furthermore, in vitro, SDF1 stimulated invasion and migration in a seminomatous
TGCT cell line (Gilbert, et al., 2009). These data provide evidence that
CXCR4/SDF1 signaling may promote TGCT metastasis.

TGFβ Superfamily
The transforming growth factor-β (TGFβ) superfamily is a cytokine
signaling family made up of more than 40 members in the human genome. The
most prominent members of this family include TGFβ, bone morphogenetic
protein (BMPs), nodal, and activin (Massague and Gomis, 2006). The
superfamily members are found in a wide variety of cell types, and are involved
in diverse biological processes, including, but not limited to, differentiation,
migration, cellular division, and adhesion. TGFβ and BMP have been implicated
in cancer growth and metastasis (Massague and Gomis, 2006) as well as germ
cell allocation and migration during development (Dudley, et al., 2007; Godin and
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Wylie, 1991), making these two members of the superfamily of interest in
testicular cancer research. Furthermore, these two members of the TGFβ
superfamily are negatively regulated by SKI (Akiyoshi, et al., 1999; Luo, et al.,
1999).

SMADs
TGFβ and BMP signal through cell surface receptors and downstream
SMAD molecules (Figure 2.2). TGFβ and BMP bind to transmembrane
serine/threonine receptors, causing them to form a heteromeric complex
composed of type I and type II receptors. When these receptors are activated by
BMP or TGFβ, they become phosphorylated, and in turn, they phosphorylate the
downstream signaling molecules, the R-SMADs. SMAD1, SMAD5, and SMAD8
are phosphorylated by activated BMP receptors (Yamashita, et al., 1996), while
SMAD2 and SMAD3 transmit TGFβ signals. Upon activation, the R-SMAD forms
a complex with the Co-SMAD, SMAD4; this complex translocates to the nucleus
and activates transcription of BMP or TGFβ target genes (Luo, 2003).
PGCs express high quantities of SMAD4, and SMAD1 is found in both
PGCs and gonadal somatic cells (Pesce, et al., 2002). SMAD1 may play a role
in PGC specification. SMAD1 knockout embryos die by 10.5 dpc, but,
interestingly, these mice produce very few, if any, PGCs (Tremblay, et al., 2001).
SMAD5 knockout is also embryonic lethal, and, these mice also display a great
reduction in PGC number or none at all (Chang and Matzuk, 2001).
Overexpression of SMAD4 in male transgenic mice causes a primary testicular
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defect which results in Leydig cell hyperplasia and germ cell ablation, leading to
infertility (Narula, et al., 2002). In light of the fact that the occurrence of testicular
germ cell tumors (TGCTs) is frequently associated with abnormalities of testicular
development, including cryptorchidism, testicular atrophy, and infertility (Kanto, et
al., 2004), this observation further implies that the BMP/SMAD signaling pathway
is important in the development of germ cells and possibly testicular cancer.

Transforming Growth Factor β
As mentioned, TGFβ has been implicated in germ cell development and
migration. TGFβ inhibits murine PGC proliferation in vitro (Godin and Wylie,
1991; Richards, et al., 1999) and also acts as a chemo-attractant for murine
PGCs in vitro (Godin and Wylie, 1991). TGFβ1 and 2 are produced by the Sertoli
cells of the fetal and newborn rodent testis, while TGFβ2 and 3 are produced in
Leydig cells, and TGFβ3 has been seen in gonocytes and spermatogonia
(Loveland, et al., 2007). TGFβ3 mRNA is the most abundantly expressed TGFβ
isoform in the pre-pubertal and adult rat testis, and increased expression of
TGFβ3 correlates with the onset of puberty and the induction of spermatogenesis
(Mullaney and Skinner, 1993).
For a cell to become malignant, it must acquire several characteristics that
allow it to evade normal regulation. The hallmark of cancer is uncontrolled
proliferation, which involves autocrine growth stimulation, loss of contact
inhibition, and protection from antiproliferative signaling. In addition to this, the
cell must acquire a mechanism for evading programmed cell death, or apoptosis.
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Cancer cells also must become immortalized, meaning they are no longer limited
to a certain number of cell divisions; they do not enter senescence. In later
stages of tumorigenesis, cancer cells form new vasculature to support the growth
of the tumor, and, finally, the cancerous cells can gain the ability to invade the
surrounding tissue and metastasize to distant sites.
TGFβ plays diverging roles in the acquisition of these properties. In the early
stages of cancer, TGFβ may act as a tumor suppressor by inhibiting proliferation,
while TGFβ signaling has been shown to promote invasion and metastasis in
cancer progression, indicating that TGFβ signaling may also promote cancer
progression (Leivonen and Kahari, 2007; Zhu, et al., 2007). TGFβ is known to
inhibit growth in many epithelial cell types, including keratinocytes, breast cancer
cells, and colon cells (Jakowlew, 2006). However in some cell types, high
concentrations of TGFβ induce growth arrest, while low concentrations actually
stimulate proliferation (Jakowlew, 2006). Nevertheless, loss of response to
TGFβ-induced growth inhibition is a mechanism by which many cancerous cells
achieve increased proliferation. Another tumor suppressing activity in which
TGFβ is involved is apoptosis. This action of TGFβ has not been as widely
studied as the growth inhibitory actions, but TGFβ has been shown to induce
apoptosis in various epithelial cells and has been implicated in controlling liver
size through apoptosis (Jakowlew, 2006).
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Figure 2.2. TGFβ superfamily signaling cascade. TGFβ and BMP bind to cell
surface transmembrane serine/threonine receptors. This binding induces the formation
of heterodimers, consisting of type-I and type-II receptors. The activated receptors
induce phosphorylation of the R-SMADs, which, in turn, form a complex with the coSMAD, SMAD4. This complex then translocates to the nucleus where it activates
transcription of TGFβ or BMP-specific target genes. This transcriptional activation is
mediated by co-activators and co-repressors.
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In contrast to the tumor suppressing activities that TGFβ displays in the
early stages of tumorigenesis, TGFβ appears to promote tumor progression by
stimulating invasion and metastasis. Specifically, TGFβ is involved in epithelial
to mesenchymal transition (EMT), which is a process by which cells become
more migratory by losing some characteristics of epithelial cells and gaining
some of the characteristics of mesenchymal cells. Increasing TGFβ levels in cell
lines causes increased tumor growth and metastasis in animal models (Jakowlew,
2006). In addition, TGFβ is more highly expressed in breast and colon
metastases compared to the primary tumors. This observation is also true for
several other types of epithelial cancers (Jakowlew, 2006). Tang et. al. (2003)
reported evidence that TGFβ switches from a tumor suppressor to a
prometastatic factor during breast cancer progression. In their experiments they
used four breast epithelial lines, all of which were derivatives of the “normal”
immortalized MCF10A cell line, that spanned the progression from “normal” to
highly malignant metastatic cancer cells. Their data supports the hypothesis that
TGFβ switches from acting as a tumor suppressor in the early stages of breast
cancer when it is anti-proliferative, to promoting metastasis in later stages of
breast cancer. Their data suggest that the switch occurs at the transition from
histologically low-grade to high-grade breast cancer (Tang, et al., 2003).

Bone Morphogenetic Proteins
Bone morphogenetic proteins (BMPs) are members of the TGFβ
superfamily of growth factor signaling molecules. At least 20 members of the
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BMP subfamily have been identified, and they are expressed in a wide variety of
tissues (Gazzerro and Canalis, 2006). The BMP subfamily was originally named
based on their role in bone formation; these proteins induced ectopic bone
formation when implanted under the skin of rodents (Ducy and Karsenty, 2000).
However, BMPs are now known to play various roles in embryonic development,
organogenesis, differentiation, and cancer. Several of the BMPs are expressed
very early in embryogenesis, around the time of gastrulation, and are involved in
organogenesis of various tissue types (Ducy and Karsenty, 2000). While the
expression pattern of BMPs is broad, they are often localized at areas of
epithelial-mesenchymal interaction (Ducy and Karsenty, 2000).
BMPs are also very important in germ cell development and
spermatogenesis. Mouse studies have shown that BMP4 and BMP8b are
necessary for the allocation of PGCs during embryonic development (Lawson, et
al., 1999; Ying, et al., 2000; Ying, et al., 2001). Additional evidence has revealed
that BMP signaling contributes to the maintenance of germ stem cells in the
Drosophila testis (Kawase, et al., 2004). BMP4 is also expressed in the early
postnatal mouse testis but is downregulated prior to puberty (Pellegrini, et al.,
2003). BMP signaling promotes proliferation of germ cells during
spermatogenesis (Puglisi, et al., 2004).
BMPs also appear to play conflicting roles in cancer progression. BMPs
have been shown to play a role in regulating stem cell differentiation (Varga and
Wrana, 2005). BMPs influence the differentiation of mesenchymal stem cells
down the chondrogenic and osteogenic lineages, but BMPs have also been
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shown to block neural differentiation (Ying, et al., 2003). BMP2 and BMP4
promote tumor growth through a variety of mechanisms, including angiogenesis,
invasion, cell growth, and cell survival (Langenfeld, et al., 2005; Langenfeld, et al.,
2006; Montesano, 2007; Raida, et al., 2005; Rothhammer, et al., 2005). About
98% of lung carcinomas display increased BMP2 expression (Langenfeld, et al.,
2005). Lung cancer cells with forced expression of BMP2 had increased
expression of ID1 and displayed enhanced tumor growth in the lungs following
intravenous injection into athymic nude mice (Langenfeld, et al., 2006). This
BMP-induced stimulation of tumor growth is associated with activation of
SMAD1/5 (Langenfeld, et al., 2006). BMP6 has been implicated in prostate
cancer development and metastasis to bone (Darby, et al., 2008). In PC3M
prostate cancer cells, treatment with BMP6 did not affect proliferation; however, it
did result in increased expression of matrix metalloproteinases, MMP-1 and
MMP-9, and also caused increased migration and invasion (Darby, et al., 2008).
However, BMP9 and BMP10 expression were found to be low or absent in
prostate tumors, and forced expression of BMP9 or -10 in PC3 prostate cancer
cells resulted in a decrease in growth, cell matrix adhesion, invasion, and
migration (Ye, et al., 2009). BMP9 and BMP10 also induced apoptosis in these
cells via a SMAD-independent pathway (Ye, et al., 2008; Ye, et al., 2009). This
suggests that BMP6 has tumor promoting activities, while BMPs 9 and 10 may
act as tumor suppressors in prostate cancer. BMP2 promotes motility and
invasion in MDA-231-D breast cancer cells and appears to be involved in
metastasis to bone, but also did not affect their proliferation (Katsuno, et al.,
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2008). BMP4 and BMP7 are increased in melanoma cells compared to normal
melanocytes, and they appear to upregulate the expression of MMP-1, -2, -3,
and -9, suggesting that BMPs may also promote metastasis in melanoma
(Rothhammer, et al., 2008; Rothhammer, et al., 2005). In colorectal cancer,
expression of BMP7 is correlated with liver metastasis and poor prognosis
(Motoyama, et al., 2008). On the other hand, BMP3 expression was found to be
down-regulated in 50 out of 56 primary colorectal tumors examined. Bisulfite
sequencing revealed hypermethylation of the BMP3 promoter in both human
colorectal tumors and HT29 colorectal carcinoma cells. Restoration of BMP3
expression in colorectal cancer cell lines resulted in growth suppression (Loh, et
al., 2008). Upon review of this collection of data, it is evident that BMPs play
diverse roles in cancer progression. Again, the role of BMP in tumorigenesis
may be dependent on the cell type and stage of cancer progression.

Inhibitors of TGFβ and BMP Signaling
The activity of TGFβ and BMP is regulated at multiple levels to maintain
coordinated cellular functions, including regulation of ligand activity, extracellular
antagonists, dominant negative pseudo-receptors, and blocking of downstream
signaling by SMADs (Gazzerro and Canalis, 2006; Massague and Chen, 2000).
TGFβ is secreted in a latent form and must be cleaved to be activated and
recognized by cell surface receptors (Massague and Chen, 2000). Several
different molecules are involved in the activation of latent TGFβ. This is a
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complicated process that is not completely understood, but thrombospondin 1
appears to be an important participator (Massague and Chen, 2000).
Extracellular antagonists prevent signaling by binding to TGFβ or BMP
and interfering with their interaction with cell surface receptors. There are four
groups of extracellular BMP antagonists: noggin, the chordin family, twisted
gastrulation, and the Dan family (Gazzerro and Canalis, 2006). Noggin is
secreted as a glycosylated protein and binds to BMP2, 4, 5, 6, and 7 with various
degrees of affinity and prevents interaction with the BMP receptors. Noggin does
not interact with TGFβ (Gazzerro and Canalis, 2006). Chordin is also a secreted
glycoprotein and interacts specifically with BMP2, 4, and 7 (Gazzerro and
Canalis, 2006). Twisted gastrulation is another secreted glycoprotein that
interacts with BMP2 and 4; it can act as both a BMP antagonist and a BMP
agonist (Gazzerro and Canalis, 2006). The Dan family is a family of
glycoprotiens, consisting of at least nine members, that is capable of binding
BMPs. Most members of the Dan family are expressed during embryogenesis,
but two members, gremlin and sclerostin, mediate BMP activity in the adult
skeleton (Gazzerro and Canalis, 2006).
BAMBI (BMP and activin membrane-bound inhibitor) is a pseudo-receptor
with extracellular domains similar to TGFβ Type I receptors but lacks the
intracellular kinase domain (Onichtchouk, et al., 1999). BAMBI can inhibit
signaling by forming heterodimers with TGFβ Type I receptors and inhibiting their
activation (Massague and Chen, 2000). BAMBI is capable of inhibiting both

31

TGFβ and BMP signals. Transcription of BAMBI is upregulated by BMP, TGFβ,
and Wnt (Gazzerro and Canalis, 2006).
An additional way to regulate TGFβ superfamily signaling is by controlling
the activity of the downstream signaling molecules, the SMADs. There are
several mechanisms that regulate SMAD signaling. SMURF1 (SMAD
ubiquitination regulator factor 1) is an E3 ubiquitin ligase that interacts with
SMAD1 and 5 but not SMAD2 or 3 (Massague and Chen, 2000; Zhu, et al.,
1999). Interaction with SMURF1 targets SMAD1 and 5 for ubiquitin-mediated
degradation, inhibiting BMP signaling (Massague and Chen 2000). BMP and
TGFβ signaling is also mediated by a group of inhibitory SMADS (I-SMADs),
SMAD6 and 7. The I-SMADs bind to Type I receptors and inhibit the
phosphorylation of R-SMADs. SMAD6 more specifically inhibits BMP signaling,
while SMAD7 inhibits both BMP and TGFβ signaling (Gazzerro and Canalis,
2006). Finally, co-repressors function to inhibit TGFβ superfamily signaling by
binding to SMADs and preventing the transcription of target genes; these include
TGIF, p300/CBP, and the SKI family (Gazzerro and Canalis, 2006; Massague
and Wotton, 2000). TGIF (transforming growth factor interacting factor) interacts
with SMAD2 and 3, and prevents TGFβ induced gene transcription by recruiting
histone deacetylases to SMAD-responsive DNA elements (Massague and
Wotton, 2000). In addition, LEFTY1 represses TGFβ and BMP signaling by
inhibiting the receptor-induced phosphorylation of the R-SMADs (Ulloa and
Tabibzadeh, 2001). The SKI family, including SKI and SNO, are also potent
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inhibitors of TGFβ and BMP signaling that function as transcriptional corepressors of SMAD proteins.

SKI
SKI was originally identified as a viral oncogene, v-ski, which is a 49 kDa
polypeptide capable of inducing transformation in avian fibroblasts (Colmenares
and Stavnezer, 1989; Stavnezer, et al., 1981). Interestingly, v-ski is also capable
of inducing myogenic differentiation in quail embryonic fibroblasts (Colmenares
and Stavnezer, 1989). c-Ski, the cellular homologue of v-ski, consists of eight
coding exons, five of which are seen in v-ski (Stavnezer, et al., 1981). SKI
functions as a transcriptional regulator; the first exon of SKI contains motifs that
are common to transcription factors, including a proline-rich region, a nuclear
localization sequence, cysteine-histidine-rich metal-binding motifs, and paired
amphipathic alpha-helices (Colmenares and Stavnezer, 1990). This region of
SKI is highly conserved in SNO (SKI-related novel), another member of the SKI
family (Nomura, et al., 1989).
SKI and SNO can function as negative regulators of the TGFβ superfamily,
through interaction with SMADs, the downstream signaling molecules of the
TGFβ superfamily (Akiyoshi, et al., 1999; Luo, et al., 1999). There are several
mechanisms by which the SKI family functions to repress TGFβ superfamily
signaling. SKI and SNO can repress TGFβ superfamily signaling by binding to
SMAD complexes and recruiting other repressors, including the
NCoR/Sin3/HDAC complex (Luo, et al., 1999; Massague and Chen, 2000).
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Additionally, SKI and SNO can block the binding of the co-activator p300/CBP to
the TGFβ-mediated R-SMADs (Akiyoshi, et al., 1999; Luo, et al., 1999). SKI can
also bind to MeCP2, a methyl-CpG-binding protein that functions in
transcriptional repression (Kokura, et al., 2001). Furthermore, interaction
between SKI or SNO and SMAD4 can prevent the formation of functional
complexes between SMAD4 and the R-SMADs (Luo, 2003). SKI, but not SNO,
has been shown to interact directly with the SMAD1/5-SMAD4 complexes to
repress transcriptional activation of BMP target genes (Takeda, et al., 2004;
Wang, et al., 2000).
The role of SKI in cancer is complex and appears to be tissue and
context-specific. As previously mentioned, SKI was classified as a protooncogene based on its ability to induce transformation in avian fibroblasts; yet
SKI can also simultaneously induce muscle differentiation in quail embryo
fibroblasts (Colmenares and Stavnezer, 1989; Stavnezer, et al., 1981). In
accordance with the transforming capability of SKI, some tumors, including
melanoma, esophageal cancer, colon cancer, and pancreatic cancer, express
high levels of SKI (Buess, et al., 2004; Fukuchi, et al., 2004; Heider, et al., 2007;
Reed, et al., 2005). SKI has also been considered pro-oncogenic because its
upregulation in some cancers, such as melanoma and prostate, results in a loss
of response to TGFβ-induced growth inhibition (Medrano, 2003; Xu, et al., 2000).
SKI has been shown to be upregulated in pancreatic cancer, and siRNAknockdown of SKI in a PANC-1 pancreatic cancer cells restored TGFβ-induced
growth inhibition (Heider, et al., 2007).
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In contrast, loss of SKI function has been linked to tumorigenesis in mice
heterozygous for a null mutation in the SKI gene (Shinagawa, et al., 2001),
suggesting SKI may also act as a tumor suppressor. Mice lacking SKI display
defects in neural and muscle development (Berk, et al., 1997; Colmenares, et al.,
2002), further indicating the importance of SKI in differentiation. Recently, it has
been reported that loss of SKI function promotes cancer progression by allowing
TGFβ to promote metastasis in lung and breast cancer cells (Le Scolan, et al.,
2008). In these studies, decreased SKI expression did not affect the proliferation
of the lung and breast cancer cells (Le Scolan et al., 2008; Zhu et al., 2008).
Thus, the role of SKI in cancer is not yet fully defined and appears to be
dependent upon the cell type and possibly the stage of cancer.

Hypothesis
The rationale for the research presented in this text is that determining the
role of SKI in testicular cancer will provide a better understanding of testicular
cancer progression. With a better understanding of the mechanisms behind
testicular cancer progression, scientists will be able to design treatments that are
aimed at the specific causes of testicular cancer, and these treatments may allow
patients a better quality of life by potentially causing less severe side effects,
such as preventing loss of fertility. It is the hypothesis of this research that
decreased SKI expression promotes testicular cancer progression by allowing
unregulated TGFβ superfamily signaling, conferring an increased ability of
testicular cancer cells to invade and metastasize.

35

CHAPTER III

RESULTS

SKI expression is decreased in TGCTs compared to normal
testis
Although SKI has been reported to have oncogenic activity in various
cancers (Buess, et al., 2004; Reed, et al., 2005), SKI-deficient heterozygous
mice have an increased susceptibility to tumorigenesis (Shinagawa, et al., 2001),
indicating that SKI may have tumor suppressor activity. RNA isolated from both
normal human testis tissue and human tumor samples, including seminoma, yolk
sac, and mixed germ cell tumors was analyzed for SKI, SNO, and CCND2 mRNA
expression using quantitative real time PCR. SKI mRNA expression was
decreased in all types of testicular tumors compared to normal testis samples
(Figure 3.1 A). The expression of SNO (Figure 3.1 B), another member of the
SKI family, was not significantly different in tumor and normal testis samples.
CCND2 was used as a positive control, as its expression is known to increase in
several types of cancer, and has specifically been shown to be increased in
testicular cancer (Bartkova, et al., 1999). As expected, CCND2 expression was
elevated in testicular tumors compared to normal tissue (Figure 3.1 C).
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Figure 3.1. Decreased SKI expression in human testicular germ cell tumors. Real
time PCR analysis comparing mRNA levels in human testicular germ cell tumors,
including seminoma (n = 16), yolk sac tumors (n = 11), and mixed tumors (n = 7), to
normal testicular tissue samples (n = 20). (A) SKI mRNA expression in germ cell
tumors compared to normal testis. (B) SNO, a member of the SKI family, was also
measured. (C) CCND2 is used as a control. mRNA levels were normalized to 18S
RNA. Data were analyzed using 2-∆∆Ct method, and error bars indicate the 95%
confidence interval.
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SKI expression varies among different human cell types
SKI expression has previously been shown to vary among different
cancerous cell types (Buess, et al., 2004; Fukuchi, et al., 2004; Heider, et al.,
2007; Reed, et al., 2005; Zhu, et al., 2007), suggesting that SKI may play
diverging roles in the development and progression of cancer dependent on cell
type and environment. In order to determine the role that SKI plays in testicular
cancer, a human embryonal carcinoma cell line, NCCIT, was used. To
determine the relative level of SKI protein expression in NCCIT testicular cancer
cells, we compared SKI expression in NCCIT cells to various other human
cancerous and normal cells (Figure 3.2). These cell lines included human
hepatocelluar carcinoma (HEPG2), human normal mammary cells (HMEC),
human breast cancer cells (MCF7 and T47D), human lung adenocarcinoma
(A549), human melanoma cells (SbCl2, WM1366, and WM9), human colorectal
carcinoma (HCT116), human neuroblastoma (SK-N-AS and SK-N-SH), and
human embryonal carcinoma (NT2/D1 and NCCIT).
In accordance with previously published data, we found that SKI is
expressed at varying levels in different cancerous and normal human cell types.
It has previously been reported that SKI expression increases with cancer
progression in human melanoma (Reed, et al., 2001). In support of this, we
found that SKI expression is higher in WM1366 human melanoma cells, which
are categorized in the vertical growth phase, compared to expression in SbCl2
human melanoma cells, which are primary melanoma cells in the radial growth
phase. SKI expression is higher still in WM9 human melanoma cells, which are
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categorized as metastatic melanoma (Figure 3.2). SKI expression was relatively
low in A549 human lung carcinoma cells (Figure 3.2), which was also previously
observed (Zhu, et al., 2007). Increased expression of SKI has previously been
reported in human colorectal carcinoma (Buess, et al., 2004), and, in accordance
with this, SKI expression was found to be high in HCT116 human colorectal
carcinoma cells (Figure 3.2). SKI was expressed at similar levels in HMEC
human normal mammary cells and MCF7 human mammary adenocarcinoma,
derived from a pleural effusion, but SKI expression was lower in T47D human
ductal carcinoma, also derived from a pleural effusion. In comparison to these
cell lines, SKI was expressed at an intermediate level in NCCIT and NT2/D1
human embryonal carcinoma cells (Figure 3.2), both of which were derived from
mediastinal metastases.

Manipulation of SKI expression in NCCIT cells
Our data shows that SKI expression is reduced in human testicular germ cell
tumors, therefore, we wanted to compare the effects of decreased SKI and
forced SKI expression using an in vitro model of testicular cancer. For these
experiments we used the human testicular cancer cell line, NCCIT, which is
classified as embryonal carcinoma (or non-seminoma). Since some SKI
expression was detected in NCCIT cells via western blotting, siRNA was used to
knockdown the levels of SKI to determine the effects of decreased SKI. Three
siRNAs against different regions of the SKI gene (designated siSKI-1, siSKI-2,
and siSKI-3) were used individually to knockdown SKI levels. A non-specific
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Figure 3.2. SKI Expression in Human Cell Lines. SKI protein levels were analyzed
by western blotting (upper panel) in various human normal and cancerous cell lines. αtubulin was used as a loading control. Protein levels were quantified by densitometry
(lower panel) and expressed relative to α-tubulin. Data represents three combined trials;
error bars indicate SEM.
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siRNA was used as a control, and cells treated with the transfection reagent
alone (mock transfection) were used to ensure that there were no adverse
consequences from the transfection procedure. Cells were treated with siRNA
over a 72 hr time period. To assess SKI knockdown, SKI mRNA and protein
levels were measured using real-time PCR and western blotting at 24, 48, and 72
hrs. In NCCIT cells, siRNAs siSKI-2 and siSKI-3 were able to knockdown SKI
mRNA and protein levels by 45-60% 48 h after transfection, while siSKI-1 siRNA
was less effective in knocking down SKI expression in NCCIT cells (Figure 3.3 A
and B).
To assess the effects of forced SKI expression on NCCIT cells, the cells
were transfected with a SKI expression vector, and the empty vector was used
as a control. SKI protein levels were assessed at 24, 48, and 72 hrs. In NCCIT
cells transfected with the SKI expression vector, SKI protein levels were
increased by 43% at 48 hrs (Figure 3.3 C).

Effects of SKI on migration in NCCIT cells
NCCIT cells were plated on Matrigel-coated plates and were treated with
one of the three SKI siRNAs or the non-specific control siRNA. A scrape was
made in the cell monolayer 48 hrs after siRNA transfection, and the cells were
analyzed for percent closure of the scrape after a 20 hr incubation period.
NCCIT cells treated with siSKI-2 and siSKI-3 siRNA accomplished a 39.1% (p <
0.05) and 40.6% (p < 0.05) increase, respectively, in percent closure of the
scraped area compared to NCCIT cells treated with the non-specific control
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Figure 3.3. siRNA Knockdown and Forced Expression of SKI in NCCIT Cells. SKI
mRNA and protein levels were measured at 48 hrs after transfection with one of three
SKI siRNAs, a control siRNA, a SKI expression vector, or the control vector. (A) siRNA
knockdown of SKI confirmed by real time PCR. Data were analyzed using 2-∆∆Ct method;
data represents three individual trials; error bars indicate the 95% confidence intervals.
(B) siRNA knockdown of SKI in NCCIT cells confirmed by western blotting; α-tubulin was
used as a loading control. Protein levels were quantified by densitometry and are
expressed relative to α-tubulin. Data represents three combined trials; error bars
indicate SEM; * indicates a significant difference with p < 0.05 as assessed by One-way
ANOVA with Bonferroni adjustment. Mock – mock transfection; Control – non-specific
siRNA; siSKI-1, siSKI-2, and siSKI-3 represent individual siRNAs. (C) Forced SKI
expression in NCCIT cells confirmed by western blotting; α-tubulin was used as a
loading control. Protein levels were quantified by densitometry and are expressed
relative to α-tubulin. Data represents three combined trials; error bars indicate SEM; *
indicates a significant difference with p < 0.05, as assessed by T-test.
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siRNA (Figure 3.4, panel A), while NCCIT cells treated with siSKI-1 siRNA
achieved a 19.7% increase (p < 0.05) in percent closure of the scraped area
compared to the control siRNA. The greater increase in migration seen in cells
treated with siSKI-2 and siSKI-3 compared to that seen with siSKI-1 correlates
with the data showing that siSKI-2 and siSKI-3 were more efficient than siSKI-1
in knocking down the level of SKI mRNA and protein.
If decreased SKI levels play an important role in promoting the metastasis
of testicular cancer cells, one would expect that forcing the expression of SKI in
these cells would have the opposite effect, inhibiting the migration of these cells.
To test this hypothesis, we forced expression of SKI in NCCIT cells by
transfecting them with a vector containing the SKI gene and performed cell
scrape assays. Cells transfected with the empty vector were used as a control.
We found that forcing expression of SKI in NCCIT cells does, indeed,
significantly decrease the percent closure of the scraped area by approximately
20% relative to the control-transfected cells (Figure 3.4, panel B). Therefore, the
level of SKI expression does appear to directly affect the ability of NCCIT cells to
migrate.

Effects of SKI on invasion in NCCIT cells
To confirm the observations seen in the cell scrape assays, Matrigel
invasion chambers were used to further assess the invasive potential of NCCIT
cells in response to the level of SKI expression. NCCIT cells treated with siSKI-2
and siSKI-3 siRNA displayed a 75% and 71% increase (p < 0.05), respectively, in
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Figure 3.4. Cell Scrape Migration Assay on NCCIT Cells. (A) Phase contrast images
of siRNA-treated NCCIT cells at 0 hr (first row) and 20 hrs (second row) after scratch
and an overlay of the 0 and 20 hr images (third row). The arrows in the overlay figures
point out the edge of the original scrape at the 0 hr time point. Bar graph represents %
closure of scratch. Data represents three trials; error bars indicate SEM; *indicates a
significant difference compared to Control siRNA with p < 0.05, as assed by One-way
ANOVA with Bonferroni adjustment. (B) Phase contrast images of NCCIT cells treated
with SKI expression vector or control vector at 0 hr (first row) and 20 hrs (second row)
after scratch and an overlay of the 0 and 20 hr images (third row). Bar graph represents
% closure of scratch; data representative of three trials; error bars indicate SEM;
*indicates a significant difference compared to Control vector with p < 0.05, as assessed
by T-test.
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the number of invading cells compared to NCCIT cells treated with the control
siRNA (Figure 3.5A). NCCIT cells treated with the siSKI-1 siRNA did not display
a significant change in the number of invading cells, which, again, correlates with
the level of knockdown seen in the cells treated with siSKI-1 siRNA. Similar to
data collected in the cell scrape assays, forcing the expression of SKI in NCCIT
cells resulted in a 44% decrease in the number of invading cells compared to the
cells treated with the control vector (Figure 3.5B).

SKI expression does not affect the growth rate of NCCIT cells
SKI expression has previously been reported to affect growth in some
cancers, including pancreatic cancer (Heider, et al., 2007). In order to determine
if SKI expression affects cellular proliferation in NCCIT cells, the growth rate of
NCCIT cells treated with SKI siRNA was determined via trypan blue dye
exclusion cell counts 24, 48, and 72 hours after transfection with siRNA, the SKI
expression vector, or the control vector (Figure 3.6A, B). There was no
significant change in the rate of growth in either the NCCIT cells treated with SKI
siRNA compared to cells treated with the control siRNA or NCCIT cells treated
with the SKI expression vector compared to cells treated with the control vector
(Figure 3.6A, B). In addition, cell counts were performed after each cell scrape
assay (data not shown), and these cell counts also revealed no difference in
growth among cells with different levels of SKI expression. These data indicate
that SKI expression does not affect proliferation in NCCIT cells.
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Figure 3.5. Matrigel Invasion Assay on NCCIT cells. (A) Number of siRNA-treated
NCCIT cells migrating through the Matrigel invasion chamber, error bars represent SEM,
*indicates a significant difference compared to Control siRNA with p < 0.05. (B) Number
of NCCIT cells treated with either the SKI expression vector or the control vector
migrating through the Matrigel invasion chamber, error bars represent SEM, *indicates a
significant difference compared to Control vector with p < 0.05 as assessed by One-way
ANOVA with Bonferroni adjustment.
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Figure 3.6. Cell Growth Measured by Trypan Blue Cell Counts. Cells were collected
at 48hrs after transfection and were counted using trypan blue dye exclusion. Data are
reported as the log of the total cell number; error bars represent SEM. (A) NCCIT cells
receiving mock transfection (Mock), treatment with the non-specific control siRNA
(Control), or treatment with one of the three SKI siRNAs (siSKI-1, siSKI-2, or siSKI-3).
(B) NCCIT cells transfected with the SKI expression vector (+SKI) or the control vector
(Control). There were no significant differences among the treatment groups as
assessed by One-way ANOVA with Bonferroni adjustment.

48

Effect of TGFβ on cell migration in SKI-knockdown cells
SKI is a negative regulator of the TGFβ superfamily signaling molecules,
including TGFβ and BMP. We have shown that SKI expression is decreased in
human testicular cancer samples compared to normal human testis samples.
We have also shown that transiently reducing the levels of SKI in NCCIT human
testicular cancer cells enhances their ability to migrate and invade in vitro.
Therefore, we sought to determine if decreased SKI expression in NCCIT
testicular cancer cells affects migration by allowing increased signaling from
TGFβ superfamily signaling molecules.
To determine this, we performed stable transfections with a SKI shRNA
vector to generate stable SKI-knockdown NCCIT cells (Figure 3.7). These cells
were exposed to TGFβ and/or TGFβ blocking antibody, and their ability to
migrate was assessed via cell scrape assays. As we previously observed with
transient SKI knockdown, cells with decreased SKI expression had significantly
increased migration compared to cells treated with the control shRNA vector
(Figure 3.8). If reduced SKI expression enhanced migration by allowing
increased TGFβ signaling, one would expect that adding TGFβ would further
enhance the migration of shSKI NCCIT cells, but adding TGFβ to shNC NCCIT
cells would not necessarily have an effect. However, treating either shSKI or
shNC NCCIT cells with TGFβ does not appear to affect their migration, nor does
treating shSKI or shNC NCCIT cells with TGFβ blocking antibody have an effect
on their migration (Figure 3.8).
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Figure 3.7. SKI knockdown in shSKI NCCIT cells. Representative western blot
showing the expression of SKI in shNC NCCIT cells and shSKI NCCIT cells. α-tubulin
was used as a loading control. Numbers indicate the level of SKI expression relative to
the level in shNC NCCIT cells.
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Figure 3.8. Effect of TGFβ on the migration of shNC and shSKI NCCIT cells. Bar
graph representing the % closure in cell scrape migration assays using shNC NCCIT
cells (black bars) and shSKI NCCIT cells (white bars) ± 0.1nM TGFβ ± 200nM TGFβ
blocking antibody. Data represents three trials; error bars indicate SEM; Groups labeled
A and B are significantly different from each other with p < 0.05 as assessed by Oneway ANOVA with Bonferroni adjustment.
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Since addition of TGFβ to SKI-knockdown NCCITs does not appear to
affect the migration of these cells, one would question whether the TGFβ
pathway is active in these cells. To explore this question, we tested TGFβinduced phosphorylation of SMAD2 in shNC and shSKI NCCIT cells. SMAD2
was readily detected by western blotting and was expressed at a constant level
regardless of the addition of TGFβ. However, p-SMAD2 was only faintly
detected by western blotting, and addition of 0.1nM TGFβ for 2 hours to either
shNC or shSKI NCCIT cells resulted in a slight induction of SMAD2
phosphorylation (1.6 fold in shNC NCCIT cells and 1.8 fold in shSKI NCCIT cells)
(Figure 3.9).

Effect of BMP on cell migration in SKI-knockdown cells
SKI is known to repress both TGFβ and BMP signaling by interacting with
SMAD proteins (Akiyoshi, et al., 1999; Luo, et al., 1999). SKI can interact with
both TGFβ-specific SMADs, SMADs 2 and 3, and BMP-specific SMADs, SMADs
1, 5, and 8, as well as the co-SMAD, SMAD4. Hence, we treated shSKI and
shNC NCCIT cells with BMP and/or noggin, a BMP inhibitor, to determine if
increased BMP signaling affects migration in SKI-deficient testicular cancer cells.
This was also assessed via cell scrape migration assays. ShSKI NCCIT cells
treated with BMP had a significant increase in percent closure of the cell scrape
compared to both untreated shSKI cells and shNC cells, untreated or treated with
BMP (Figure 3.10). Treating shNC NCCIT cells with BMP did not affect their
migration (Figure 3.10). In addition, treating shSKI cells with noggin, a BMP

52

shNC shSKI
TGFβ

-

+

-

+

p-SMAD2
α-tubulin
1.0 1.6

1.0 1.8

SMAD2
α-tubulin

Figure 3.9. Induction of SMAD2 phosphorylation by TGFβ in shNCCIT cells. Upper
panel is a representative western blot showing the expression of phospho-SMAD2 in
shNCCIT cells ± TGFβ treatment (0.1nM) for 2 hrs. α-tubulin was used as a loading
control. Numbers indicate the level of p-SMAD2 relative to the level in shNC NCCIT
cells – TGFβ. Lower panel is a representative western blot showing the expression of
SMAD2 in shNCCCIT cells ± TGFβ treatment. α-tubulin was used as a loading control.
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inhibitor, reduced their level of migration back to the level of untreated shNC
NCCIT cells (Figure 3.10). Treating shNC NCCIT cells with noggin also slightly
reduced their migration. This indicates that in NCCIT cells, reduced SKI
expression enhances BMP signaling, which promotes migration.
To demonstrate the activity of the BMP pathway in NCCIT cells, shNC or
shSKI NCCIT cells were treated with BMP, noggin, or both and assessed for
phosphorylation of SMAD1/5/8. Treating shNC or shSKI NCCIT cells with BMP
induced the phosphorylation of SMAD1/5/8 (Figure 3.11). This effect was
inhibited in the presence of noggin. As expected, SMAD1/5/8 phosphorylation
was induced by BMP regardless of SKI expression. P-SMAD1/5/8 expression
was approximately 2.3 and 2.5 fold higher in shNC NCCIT and shSKI NCCIT
cells, respectively, treated with BMP compared to untreated cells. Treatment
with BMP, noggin, or both did not affect the level of SMAD5 expression (Figure
3.11 lower panel). As expected, the presence of SKI did not affect SMAD
phosphorylation because SKI does not act at the level of inhibiting SMAD
phosphorylation, but, rather, prevents SMAD-induced gene transcription.
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Figure 3.10. Effect of BMP on migration of shNC and shSKI NCCIT cells. Bar
graph representing the percent closure in cell scrape migration assays using shNC
NCCIT cells (black bars) and shSKI NCCIT cells (white bars) ± 10ng/mL BMP, ±
0.1µg/mL noggin. Data represents the mean of three trials; error bars indicate SEM;
Groups labeled A, B, C and D are each significantly different from each other with p <
0.05 as assessed by One-way ANOVA with Bonferroni adjustment.
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Figure 3.11. Phosphorylation of SMAD1/5/8 by BMP4. The upper panel is a
representative western blot showing the expression of phospho-SMAD1/5/8 in shNCCIT
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin treatment for 2 hrs. Numbers indicate the
level of p-SMAD1/5/8 relative to p-SMAD1/5/8 levels in shNC NCCIT cells + BMP. The
lower panel shows SMAD5 expression in shNCCIT cells ± 10ng/mL BMP, ± 0.1µg/mL
noggin treatment for 2 hrs. α-tubulin was used as a loading control for both western
blots..
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SKI Expression in shNC and shSKI NCCIT cells treated with BMP
and/or Noggin
Real time PCR analysis was used to test the level of SKI knockdown in
shSKI NCCIT cells compared to shNC NCCIT cells and to determine if addition of
BMP or noggin affects the level of SKI. SKI mRNA expression was significantly
reduced by about 80% in shSKI NCCIT cells compared to shNC NCCIT cells
(Figure 3.12). Addition of BMP and/or noggin did not significantly alter the level
of SKI mRNA in these cells.

Microarray Analysis
We found that experimentally reducing SKI expression in NCCIT cells
resulted in an enhanced invasive phenotype. Therefore we next sought to
determine if reducing SKI expression in these NCCIT cells allowed an
upregulation of genes involved in promoting metastasis and downregulation of
genes that function to inhibit cellular invasion. Furthermore, since SKI is a
transcription factor and a co-repressor of the TGFβ superfamily, we were
interested in identifying changes in the expression patterns of genes involved in
TGFβ superfamily signaling, especially genes involved in BMP signaling because
we have shown that BMP enhances the invasive phenotype seen in shSKI
NCCIT cells. In order to identify potential downstream targets of SKI that may
play a role in metastasis, microarray analysis was performed to compare the
gene expression profile of shSKI NCCIT cells to that of the shNC NCCIT cells.
Statistical analysis of microarray (SAM) and gene set enrichment analysis (GSEA)
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Figure 3.12. SKI mRNA expression in shNCCIT cells treated with BMP and/or
noggin. Real time PCR analysis comparing SKI mRNA expression in shNC NCCIT
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL
BMP, ± 0.1µg/mL noggin. RNA levels were normalized to 18S RNA. Data represents
three individual trials and was analyzed using 2-∆∆Ct method; error bars indicate the 95%
confidence interval.
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(http://www.broadinstitute.org/gsea) were used to identify significant genes and
gene families that were differentially expressed in shSKI NCCIT cells compared
to shNC NCCIT cells.
Statistical analysis of microarrays (SAM) revealed 963 human gene
probes were differentially expressed in shSKI and shNC NCCIT cells. Of these
differentially expressed genes, 593 probes were upregulated by at least 1.5 fold
in shSKI NCCIT cells, and 370 probes were downregulated by at least 1.5 fold in
shSKI NCCIT cells compared to shNC NCCIT cells. The differentially expressed
genes belong to diverse signaling pathways and are involved in a variety of
cellular processes.
Gene Set Enrichment Analysis (GSEA) was used to identify gene sets
involved in specific biological processes that were significantly upregulated in
shSKI NCCIT cells compared to shNC NCCIT cells. GSEA uses four key
statistics for determining gene set enrichment. These include the enrichment
score (ES), the normalized enrichment score (NES), the false discovery rate
(FDR), and the nominal p-value. The ES value ranks the gene sets according to
the degree to which they are over-represented at the top or bottom of a ranked
list of genes. A positive ES indicates a correlation with the shSKI phenotype,
while a negative ES indicates a correlation with the control phenotype. If several
genes from a gene set are clustered at the top of the ranked list, the ES value
would be higher, and that gene set would be more strongly correlated with the
shSKI phenotype. The NES can be used to compare analysis results across
gene sets because it accounts for differences in gene set size and in correlations
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between gene sets and the expression dataset. The FDR is the estimated
probability that a gene set with a given NES represents a false positive finding.
The nominal p value provides an evaluation of the statistical significance of the
enrichment score for a single gene set (http://www.broadinstitute.org/gsea). The
FDR is adjusted for gene set size and multiple hypothesis testing, but the
nominal p value is not. The family-wise error rate (FWER) is a more stringent
measure of significance that corrects for multiple hypothesis testing. This more
conservative cutoff resulted in only a few statistically significant results with
FWER less than 0.05. In our analysis we were primarily interested in identifying
potential targets of SKI that may play a role in metastasis, therefore we
considered gene sets with both an FDR less than 0.25 and a nominal p value
less than 0.05.
Within the gene sets, GSEA provides the rank in gene list, the rank metric
score, and the running ES. GSEA assigns each gene a rank metric score, which
is computed using a “Signal2Noise” measurement that uses the difference of
means scaled by the standard deviation. This provides a measurement of the
gene’s correlation with the phenotype being studied and is used to position the
gene in the ranked list. The rank values go from positive to negative as you
move down the list, with a higher positive value indicating a stronger correlation
with the shSKI phenotype and a negative value indicating a correlation with the
control phenotype. The rank in gene list indicates the position of the gene in a
ranked list of genes. Thus a lower value indicates a higher position on the
ranked list and a stronger correlation with the shSKI phenotype. The running ES
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is the enrichment score at this point in the ranked list of genes. During the
analysis, GSEA creates a running sum statistic by walking down the ranked list of
genes, and this value is increased when the gene belongs to the gene set being
tested. The magnitude of the ES from zero is indicative of the correlation of that
gene with the phenotype, with an ES closer to one being a strong correlation.
GSEA identified 101 gene sets that were enriched in shSKI NCCIT cells
compared to shNC NCCIT cells with a nominal p-value (p-nominal) less than
0.05 and a false discovery rate (FDR) less than 0.25 (Table 3.1). Of these 101
gene sets, the gene set “Regulation of MAP Kinase Activity” contained 20 genes
that were enriched in shSKI NCCIT cells compared to shNC NCCIT cells with a
family-wise error rate p-value (FWER) of less than 0.05, indicating a higher level
of significance (Table 3.2). Some interaction between the MAPK and BMP
pathways has previously been shown to be involved in cell fate determination.
FGF8 and IGF2, both of which activate MAPK signaling, have been shown to
inhibit nuclear localization of SMAD1 (Massague, et al., 2005). However, these
specific genes were not identified through GSEA as being enriched in the SKIknockdown cells. It is possible that upregulation of MAPK signaling may be a
compensation mechanism to the increased activity of the BMP pathway in SKIknockdown cells. Activation of the Ras/MAPK pathway has also been shown to
inhibit SMAD2 nuclear localization, preventing TGFβ signaling (Massague, 2003).
It is possible that alterations in MAPK signaling may contribute to the lack of
response seen with the addition of TGFβ to the shSKI NCCIT cells. A specific
link between SKI and the MAPK pathway has not been shown, thus our data
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suggest that there may be further interaction between MAPK signaling and TGFβ
superfamily signaling.
Also of interest to this research is the gene set “Transforming Growth
Factor Beta Receptor Signaling Pathway,” which met the dual criteria of nominal
p-value less than 0.05 and FDR less than 0.25 (Table 3.3). This signaling
pathway is of interest because SKI is known to be a co-repressor of the TGFβ
superfamily. Both SMAD7 and LEFTY1, which are known to inhibit TGFβ
signaling, were enriched in SKI knockdown cells. This was also seen in the SAM
analysis (Table 3.6). Upregulation of these genes may contribute to the lack of
response seen with the addition of TGFβ to shSKI NCCIT cells.
In review of the SAM data set, other signaling families of interest were
identified, including the WNT signaling family, genes belonging to the family of
chemokines and their receptors, and additional TGFβ superfamily signaling
genes. Several genes from the WNT signaling family (Table 3.4) were
differentially expressed in shSKI and shNC NCCIT cells. The importance of the
WNT signaling pathway in colorectal cancer has been widely reported, and the
WNT pathway has also been implicated in epithelial to mesenchymal transition
(reviewed in (Huang and Du, 2008), which suggests that this signaling family
may play a role in the enhanced invasive phenotype seen in the shSKI NCCIT
cells.
Additionally, several chemokines and chemokine receptors were
differentially expressed in shSKI and shNC NCCIT cells (Table 3.5).
Chemokines and their receptors are known to play an important role in
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tumorigenesis, especially in tissue directed metastasis (Vandercappellen, et al.,
2008). Based on our observed phenotype in SKI-knockdown cells, CXCR4 is of
particular interest in this group of chemokines because CXCR4 has previously
been implicated in testicular cancer metastasis. CXCR4 was upregulated in
shSKI NCCIT cells compared to shNC NCCIT cells. This finding supports our
hypothesis that decreased SKI expression promotes metastasis in testicular
cancer, and it also suggests that SKI may regulate the expression of CXCR4 in
testicular cancer cells.
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Table 3.1. Gene Sets Enriched in shSKI NCCIT Cells Identified by GSEA.
NAME OF GENE SET
Transcription Initiation
Protein DNA Complex Assembly
Positive Regulation of MAP Kinase Activity
Transcription Initiation from RNA Polymerase II
Promoter
Activation of MAPK Activity
Regulation of Mitotic Cell Cycle
Cell Structure Disassembly during Apoptosis
Apoptotic Nuclear Changes
Amino Acid Transport
Negative Regulation of MAP Kinase Activity
Amine Transport
Transforming Growth Factor Beta Receptor
Signaling Pathway
Glycoprotein Metabolic Process
Regulation of MAP kinase Activity
Negative Regulation of Transferase Activity
Glycoprotein Biosynthetic Process
Regulation of Organelle Organization and
Biogenesis
Central Nervous System Development
DNA Catabolic Process
Transmembrane Receptor Protein Serine
Threonine Kinase Signaling Pathway
Response to Oxidative Stress
Regulation of Cytoskeleton Organization and
Biogenesis
Regulation of Hydrolase Activity

# of
GENES
35
48
46
29

ES

NES

0.5738
0.5146
0.5157
0.5998

2.1093
1.9813
1.9244
1.9896

0.0000
0.0000
0.0000
0.0000

0.0138
0.0308
0.0367
0.0376

0.0110
0.0530
0.0990
0.0440

RANK AT
MAX
1717
833
4160
1717

40
22
18
19
26
17
38
36

0.5216
0.5415
0.5250
0.4939
0.5672
0.6590
0.5268
0.5141

1.9299
1.8599
1.9436
1.8827
1.8621
1.8910
1.8231
1.8143

0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000

0.0396
0.0415
0.0421
0.0427
0.0450
0.0452
0.0464
0.0477

0.0890
0.1650
0.0810
0.1440
0.1610
0.1380
0.2480
0.2640

2645
4833
1920
1920
971
3196
971
2714

90
66
35
74
40

0.4294
0.5468
0.5344
0.4304
0.4514

1.8248
2.0014
1.8266
1.8295
1.7190

0.0000
0.0000
0.0000
0.0000
0.0000

0.0487
0.0500
0.0510
0.0521
0.0696

0.2430
0.0370
0.2330
0.2260
0.4680

1069
3718
3581
1069
3877

121
23
47

0.3945
0.4721
0.4056

1.7582
1.7627
1.7196

0.0000
0.0000
0.0000

0.0696
0.0702
0.0718

0.3680
0.3610
0.4670

4987
1802
2714

45
30

0.4269
0.4925

1.7649
1.7260

0.0000
0.0000

0.0718
0.0758

0.3500
0.4500

1842
3877

75

0.4409

1.7318

0.0000

0.0774

0.4360

4997
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p-nominal

FDR

FWER

NAME OF GENE SET
Positive Regulation of Catalytic Activity
Negative Regulation of Catalytic Activity
Positive Regulation of Transferase Activity
Protein Kinase Cascade
Activation of Immune Response
Apoptotic Program
Regulation of Catalytic Activity
Organic Acid Transport
Regulation of Transferase Activity
Carboxylic Acid Transport
Enzyme Linked Receptor Protein Signaling
Pathway
Protein Secretion
Homeostasis of Number of Cells
Cell Substrate Adhesion
Cell Matrix Adhesion
Response to Abiotic Stimulus
Regulation of Signal Transduction
Regulation of Kinase Activity
MAPKKK Cascade GO 0000165
Mesoderm Development
Chromosome Segregation
Glycolipid Metabolic Process
Organelle Organization and Biogenesis
Secretion
Regulation of Protein Kinase Activity
Oxygen and Reactive Oxygen Species Metabolic
Process
Positive Regulation of Transcription from RNA
Polymerase II Promoter

# of
GENES
158
68
85
286
16
59
268
42
159
41
139

ES

NES

0.4067
0.3798
0.4080
0.3542
0.6843
0.4217
0.3336
0.4124
0.3424
0.4180
0.3190

1.7270
1.6866
1.6769
1.6784
1.6813
1.6514
1.6316
1.6202
1.6027
1.5956
1.5842

0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000

0.0783
0.0815
0.0821
0.0829
0.0832
0.0866
0.0909
0.0926
0.1006
0.1050
0.1131

0.4480
0.5600
0.5790
0.5780
0.5700
0.6340
0.6780
0.7050
0.7430
0.7580
0.7750

RANK AT
MAX
4433
3581
2645
3866
3006
4433
4917
971
3718
971
4401

31
20
37
36
87
219
155
103
21
32
16
469
174
153
20

0.3958
0.5226
0.4951
0.4787
0.4134
0.3099
0.3331
0.4030
0.5195
0.5086
0.5776
0.2734
0.3212
0.3286
0.6436

1.5519
1.7366
1.6765
1.6333
1.6947
1.4788
1.5612
1.6765
1.5343
1.7238
1.8312
1.5045
1.4673
1.5380
1.7050

0.0000
0.0020
0.0040
0.0040
0.0040
0.0041
0.0041
0.0041
0.0042
0.0059
0.0059
0.0061
0.0062
0.0062
0.0063

0.1283
0.0778
0.0780
0.0911
0.0776
0.1600
0.1250
0.0801
0.1349
0.0739
0.0551
0.1484
0.1583
0.1335
0.0760

0.8370
0.4240
0.5790
0.6730
0.5220
0.9360
0.8200
0.5790
0.8740
0.4550
0.2230
0.9070
0.9450
0.8650
0.5030

3322
3790
3216
3216
5363
3826
3718
2645
6231
472
601
2644
3334
3718
4224
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0.3795

1.5523

0.0078

0.1299

0.8370

3508
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p-nominal

FDR

FWER

NAME OF GENE SET
Positive Regulation of Immune Response
Regulation of Molecular Function
Positive Regulation of RNA Metabolic Process
Mitochondrial Transport
Actin Filament Organization
Positive Regulation of Hydrolase Activity
Brain Development
Positive Regulation of Signal Transduction
Cellular Cation Homeostasis
Mitotic Sister Chromatid Segregation
Sulfur Metabolic Process
Response to UV
Axon Guidance
Mitochondrial Organization and Biogenesis
ER to Golgi Vesicle Mediated Transport
Cation Homeostasis
Meiotic Cell Cycle
Nucleotide Excision Repair
Secretion by Cell
IkappaB Kinase NFkappaB Cascade
Sister Chromatid Segregation
Positive Regulation of Nucleobase Nucleoside
Nucleotide and Nucleic Acid Metabolic Process
Lipid Biosynthetic Process
Transmembrane Receptor Protein Tyrosine
Kinase Signaling Pathway
Positive Regulation of Transcription DNA
Dependent
Activation of NFkappaB Transcription Factor
Membrane Lipid Biosynthetic Process

# of
GENES
26
316
118
20
24
51
51
122
96
16
35
25
22
47
18
99
33
20
112
109
17
150

ES

NES

0.6119
0.3036
0.3576
0.4701
0.5038
0.4937
0.4229
0.3390
0.4445
0.5633
0.4868
0.4798
0.4497
0.4152
0.6646
0.4364
0.3765
0.5083
0.3361
0.3689
0.5310
0.3355

1.6596
1.5693
1.5650
1.6558
1.6566
1.6456
1.6102
1.4179
1.6229
1.7426
1.7202
1.6534
1.5003
1.6108
1.7031
1.6043
1.5473
1.6299
1.4592
1.4697
1.6345
1.4911

0.0080
0.0082
0.0099
0.0101
0.0120
0.0121
0.0138
0.0145
0.0150
0.0154
0.0160
0.0162
0.0162
0.0180
0.0210
0.0213
0.0216
0.0220
0.0220
0.0222
0.0230
0.0240

0.0884
0.1256
0.1255
0.0871
0.0886
0.0883
0.0978
0.1946
0.0925
0.0763
0.0741
0.0868
0.1472
0.0992
0.0747
0.1007
0.1279
0.0902
0.1668
0.1572
0.0915
0.1497

0.6060
0.8020
0.8150
0.6190
0.6150
0.6470
0.7220
0.9730
0.7000
0.4110
0.4670
0.6300
0.9140
0.7210
0.5040
0.7390
0.8490
0.6840
0.9630
0.9410
0.6720
0.9200

RANK AT
MAX
3191
2645
5734
588
3877
4997
2507
4260
4105
2181
6219
3222
1582
3644
2953
4105
3063
1481
3334
3826
2181
5078

96
82

0.3520
0.3016

1.4942
1.3972

0.0266
0.0276

0.1496
0.2054

0.9180
0.9840

4453
3697

116

0.3411

1.4917

0.0279

0.1506

0.9200

5734

18
48

0.4725
0.4475

1.5628
1.5510

0.0293
0.0295

0.1254
0.1275

0.8190
0.8410

2277
4213
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p-nominal

FDR

FWER

NAME OF GENE SET
Regulation of GTPase Activity
Regulation of IkappaB Kinase NFkappaB Cascade
Regulation of Cytokine Production
Maintenance of Localization
Positive Regulation of Caspase Activity
Cellular Component Disassembly
Positive Regulation of Cytokine Production
Ion Homeostasis
Negative Regulation of Cellular Component
Organization and Biogenesis
Regulation of Intracellular Transport
Centrosome Organization and Biogenesis
Cellular Homeostasis
Response to Organic Substance
Response to Radiation
Leukocyte Migration
Negative Regulation of Cell Cycle
Regulation of Protein Import into Nucleus
Protein Amino Acid N-Linked Glycosylation
Regulation of Nucleocytoplasmic Transport
Microtubule Organizing Center Organization and
Biogenesis
Positive Regulation of IkappaB Kinase NFkappaB
Cascade
Positive Regulation of Response to Stimulus
Response to Chemical Stimulus
Cellular Protein Complex Assembly

# of
GENES
16
89
25
22
30
33
15
119
28

ES

NES

p-nominal

FDR

FWER

0.6576
0.3705
0.4534
0.4646
0.4728
0.3383
0.5410
0.4165
0.4108

1.6401
1.4337
1.4718
1.5074
1.5094
1.4397
1.5394
1.5551
1.4703

0.0296
0.0297
0.0306
0.0308
0.0319
0.0332
0.0333
0.0356
0.0364

0.0910
0.1832
0.1613
0.1486
0.1480
0.1803
0.1338
0.1289
0.1597

0.6660
0.9680
0.9400
0.9050
0.9040
0.9680
0.8630
0.8310
0.9410

RANK AT
MAX
2501
3826
4084
1919
4433
3644
4084
4105
3877

25
15
137
29
58
16
79
16
30
22
16

0.5016
0.5518
0.3971
0.3699
0.4089
0.5836
0.3370
0.5630
0.4339
0.5176
0.5404

1.5508
1.5332
1.5662
1.4530
1.5287
1.5133
1.4102
1.6280
1.4089
1.6371
1.5061

0.0365
0.0367
0.0392
0.0394
0.0395
0.0397
0.0413
0.0425
0.0426
0.0431
0.0441

0.1260
0.1343
0.1268
0.1686
0.1371
0.1453
0.1977
0.0900
0.1977
0.0918
0.1481

0.8450
0.8750
0.8100
0.9640
0.8800
0.8990
0.9800
0.6870
0.9810
0.6710
0.9050

7129
3099
4105
4987
3445
1968
6373
5632
704
5970
3099

83

0.3872

1.4363

0.0457

0.1828

0.9680

3826

38
305
33

0.4759
0.3074
0.4256

1.4736
1.3973
1.4955

0.0482
0.0487
0.0494

0.1624
0.2067
0.1503

0.9390
0.9840
0.9180

3191
5257
3355

ES = enrichment score; NES = normalized enrichment score; p-nominal = nominal p-value; FDR = false discovery rate; FWER =
family wise error rate. Gene sets highlighted in red are further discussed.
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Table 3.2. Regulation of MAP Kinase Activity Genes Upregulated in shSKI NCCIT Cells.
REGULATION OF MAP KINASE ACTIVITY
GENE NAME

GENE TITLE

ADRA2C
DUSP6
CXCR4
SOD1

adrenergic, alpha-2C-, receptor
dual specificity phosphatase 6
chemokine (C-X-C motif) receptor 4
superoxide dismutase 1, soluble (amyotrophic
lateral sclerosis 1 (adult))
MyoD family inhibitor
dual specificity phosphatase 22
tumor protein D52-like 1
dual specificity phosphatase 16
G protein pathway suppressor 2
MAP-kinase activating death domain
regulator of G-protein signaling 4
CD24 molecule
Mitogen-activated protein kinase kinase kinase 5
mitogen-activated protein kinase kinase kinase
kinase 5
fibroblast growth factor 2 (basic)
dual specificity phosphatase 9
adrenergic, beta-2-, receptor, surface
tribbles homolog 3 (Drosophila)
p21/Cdc42/Rac1-activated kinase 1 (STE20
homolog, yeast)

ZAK
MDFI
DUSP22
TPD52L1
DUSP16
GPS2
MADD
RGS4
CD24
MAP3K5
MAP4K5
FGF2
DUSP9
ADRB2
TRIB3
PAK1

RANK IN GENE
LIST
28
118
175
383

RANK METRIC
SCORE
3.569720984
2.6670959
2.362784386
1.804534674

RUNNING
ES
0.099149056
0.17067271
0.23489298
0.27777663

CORE
ENRICHMENT
Yes
Yes
Yes
Yes

716
846
876
1252
1346
1498
1564
1806
1851
2135
2584

1.414972186
1.300608873
1.286507726
1.064876556
1.026440144
0.969061494
0.940572977
0.858003378
0.845130682
0.774060726
0.679615498

0.30503437
0.3367004
0.37172356
0.38754058
0.4128619
0.434396
0.4583579
0.47339702
0.49546805
0.5065747
0.50883806

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

2645
3196
3355
3559
3718

0.669743836
0.583537579
0.560504258
0.534068823
0.514676154

0.5253856
0.5211242
0.5309276
0.53830016
0.54681724

Yes
Yes
Yes
Yes
Yes

“Rank in gene list” indicates the position of the gene in a ranked list of genes. “Rank metric score” is a score used to position the
gene in the ranked list and is computed using a “Signal2Noise” measurement that uses the difference of means scaled by the
standard deviation. The “Running ES” is the enrichment score at this point in the ranked list of genes. Genes with a Yes value in the
“Core enrichment” column contribute to the leading-edge subset within the gene set. This is the subset of genes that contributes
most to the enrichment result.
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Table 3.3. Transforming Growth Factor Beta Receptor Signaling Pathway Genes Upregulated in shSKI NCCIT Cells.
TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY
GENE NAME GENE TITLE
RANK IN
RANK METRIC
GENE LIST
SCORE
SMAD7
SMAD, mothers against DPP homolog 7
32
3.454453945
(Drosophila)
MAP3K7
mitogen-activated protein kinase kinase
245
2.102769136
kinase 7
EID2
EP300 interacting inhibitor of differentiation 2
284
2.000285625
LEFTY1
left-right determination factor 1
494
1.66031909
FMOD
Fibromodulin
613
1.515063643
TGFBRAP1
transforming growth factor, beta receptor
1009
1.202226281
associated protein 1
SMAD3
SMAD, mothers against DPP homolog 3
1927
0.828692615
(Drosophila)
TGFBR1
transforming growth factor, beta receptor I
2340
0.730790496
(activin A receptor type II-like kinase, 53kDa)
ACVR1
activin A receptor, type I
2391
0.717254817
SNX6
sorting nexin 6
2714
0.65763092

RUNNING
ES
0.14178942

CORE
ENRICHMENT
Yes

0.22088137

Yes

0.302254
0.36314425
0.4214333
0.4563893

Yes
Yes
Yes
Yes

0.4563156

Yes

0.47112036

Yes

0.4989351
0.5140854

Yes
Yes

“Rank in gene list” indicates the position of the gene in a ranked list of genes. “Rank metric score” is a score used to position the
gene in the ranked list and is computed using a “Signal2Noise” measurement that uses the difference of means scaled by the
standard deviation. The “Running ES” is the enrichment score at this point in the ranked list of genes. Genes with a Yes value in the
“Core enrichment” column contribute to the leading-edge subset within the gene set. This is the subset of genes that contributes
most to the enrichment result.
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As expected based on SKI’s known function as a co-repressor of the
TGFβ superfamily, genes belonging to this signaling pathway were differentially
expressed in shSKI NCCIT cells compared to shNC NCCIT cells as well (Table
3.3). The expression pattern of the genes in the TGFβ superfamily may
contribute to our finding that addition of BMP into our cell scrape assays resulted
in an enhanced invasive phenotype of the shSKI NCCIT cells, while addition of
TGFβ had no effect. For example, the microarray data shows that LEFTY1 and
SMAD7, both of which can function as inhibitors of TGFβ signaling, were
upregulated in shSKI NCCIT cells compared to shNC NCCIT cells. Furthermore,
FST (follistatin), which specifically represses BMP signaling, was downregulated
in shSKI NCCIT cells. These data suggest that SKI may regulate the expression
of these negative regulators of the TGFβ superfamily signaling molecules.
The data indicate that decreased SKI may promote metastasis in testicular
cancer. Therefore, we were interested in differentially expressed genes that may
be involved in cellular migration and invasion in addition to genes that may be
involved in TGFβ superfamily signaling. We selected certain genes from the list
of differentially expressed genes, based on a review of the literature, which we
believed to be potentially involved in the mechanism behind which decreased
SKI expression promotes invasion of testicular cancer cells. Real time PCR
analysis was used to confirm the changes in gene expression of LEFTY1 (Figure
3.13A), ADAMTS1 (Figure 3.13B), and CXCR4 (Figure 3.14). Real time PCR
analysis showed that these genes were, indeed, upregulated in shSKI NCCIT
cells compared to shNC NCCIT cells by 1.7, 2.6, and 5.5 fold, respectively. This
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Table 3.4. WNT signaling family genes identified by microarray analysis.
Gene

Gene Description

Gene Function

Fold
change

HHIP

Hedgehog interacting protein

Regulator of vertebrate hedgehog signaling
pathway

2.6

WNT3

WNT family member 3

Involved in primary axis formation in the
mouse

2.4

PPP3CC

Protein phosphatase 3 (formerly B2)
gamma isoform

Ca(2+) dependent modifier of phosphorylation
status

2.2

FZD2

Frizzled homolog 2

G-protein coupled receptor; binds WNT protein
and induces intracellular calcium release

2.1

MAP3K7

Mitogen activated protein kinase kinase
kinase 7 (TGFβ activated kinase 1)

Stimulated in response to TGFβ and BMP;
mediator of TGFβ superfamily transcription

1.7

PPP2R1B

Protein phosphatase 2 (formerly 2A),
regulatory subunit A, beta isoform

Downregulates the MAPK cascade

1.7

TCF7

Transcription factor 7

May act as a feedback repressor of β-catenin
target genes

0.6

AXIN2

Axis inhibitor 2 (conductin)

role in β-catenin stability

0.5

PLCB4

Phospholipase C beta 4

Plays a role in the light response in retinas

0.5

PTCH1

Patched 1 transmembrane protein

Represses transcription in certain cells of
genes from the TGFβ and WNT families

0.4

FZD8

Frizzled homolog 8

Receptor for secreted WNT glycoproteins

0.3

Red numbers indicate increased expression and blue numbers indicate decreased
expression in shSKI NCCIT cells compared to shNC NCCIT cells. Gene functions
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez.
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Table 3.5. Chemokine genes identified by microarray analysis.
Gene

Gene Description

Gene Function

Fold
change

CXCR4

Chemokine (C-X-C motif) receptor 4

Receptor for SDF1; invovled in HIV
infection; implicated in cancer metastasis

6.5

CCL26

Chemokine (C-C motif) ligand 26

Member of chemokine family; plays a role in
cell trafficking and immune system function

2.3

CCL2

Chemokine (C-C motif) ligand 2

Recruitment of monocytes to sites of injury
and infection

2.1

CXCR7

Chemokine (C-X-C motif) receptor 7

Alternate receptor for SDF1; involved in cell
growth, survival, and adhesion

1.9

CX3CL1

Chemokine (C-X3-C motif) ligand 1

Mediator of cellular migration; attracts
natural killer cells to sites of infection

0.5

Red numbers indicate increased expression and blue numbers indicate decreased
expression in shSKI NCCIT cells compared to shNC NCCIT cells. Gene functions
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez.

Table 3.6. TGFβ superfamily signaling genes identified by microarray analysis.
Gene

Gene Description

Gene Function

Fold
Change

GDF3

Growth differentiation factor 3

BMP family member; expression decreases with
differentiation of cultured human embryonic stem cells

2.0

LEFTY1

L-R determination factor 1

TGFβ superfamily inhibitor; also involved in left-right
polarity in early development

1.7

MAP3K7

Mitogen activated protein
kinase kinase kinase 7 (TGFβ
activated kinase 1)

Stimulated in response to TGFβ and BMP; mediator of
TGFβ superfamily transcription

1.7

SMAD7

Inhibitory SMAD 7

TGFβ superfamily inhibitor by inhibition of R-SMAD
phosphorylation

1.5

SPP1

Secreted phosphoprotein 1
(osteopontin)

Cytokine involved in bone formation and immune
response

0.5

FST

Follistatin

Negative regulator of the TGFβ superfamily

0.5

SKI

SKI protooncogene

Negative regulator of the TGFβ superfamily

0.4

ACVR1C

Activin A receptor, type 1C

Receptor for the TGFβ superfamily signaling
molecules

0.3

Red numbers indicate increased expression and blue numbers indicate decreased
expression in shSKI NCCIT cells compared to shNC NCCIT cells. Gene functions
descriptions are from Online Mendelian Inheritance in Man (OMIM) and Gene Entrez.
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B
3

ADAMTS-1 mRNA Expression Relative to 18S mRNA

LEFTY1 mRNA Expression Relative to 18S mRNA

A

2.5

2

1.5

1

0.5

0

shNC NCCIT

shSKI NCCIT

3.5
3
2.5
2
1.5
1
0.5
0
shNC NCCIT

shSKI NCCIT

Figure 3.13. LEFTY1 and ADAMTS-1 expression in shSKI NCCIT cells compared
to shNC NCCIT cells. Real time PCR analysis comparing LEFTY1 (A) and ADAMTS1
(B) expression in shSKI NCCIT cells and shNC NCCIT cells. RNA levels were
normalized to 18S RNA. Data represents six individual trials and was analyzed using 2∆∆Ct
method; error bars indicate the 95% confidence interval.
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confirmed the microarray SAM results showing that LEFTY1, ADAMTS1, and
CXCR4 were upregulted in shSKI NCCIT cells by 1.7, 2.1, and 6.5 fold,
respectively.

SMAD Binding Elements in Promoters of Target Genes
In order to determine if potential target genes of SKI that were identified by
microarray analysis were transcriptionally regulated by SMADs, promoter
analysis of specific genes was performed to identify the presence of BMP and/or
TGFβ regulatory elements. BMP and TGFβ signaling is transmitted inside the
cell by SMADs. R-SMADs, SMAD 1, 5, and 8, are phosphorylated in response to
BMP signals, while R-SMADs, SMADs 2 and 3, are phosphorylated in response
to TGFβ signals. These phosphorylated R-SMADs form a complex with the coSMAD, and these complexes are able to initiate target gene transcription by
binding to the promoter region with additional co-factors (Massague and Wotton,
2000). SKI is known to repress both BMP and TGFβ signaling by interfering with
SMAD-mediated gene transcription (Akiyoshi, et al., 1999; Luo, et al., 1999;
Stroschein, et al., 1999). Cell scrape migration experiments revealed that
addition of BMP to SKI-knockdown NCCIT cells resulted in an enhanced invasive
phenotype, while addition of TGFβ had no effect. Therefore, we were interested
in identifying SKI-responsive genes that are regulated by BMP. The presence of
SMAD 1/5/8 binding elements in the promoter region of a gene would be
evidence of regulation by BMP. TGFβ-regulated SMAD binding elements were
also considered to determine the specificity of gene regulation.
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A literature search revealed several potential SMAD regulatory elements
for both BMP and TGFβ responsive genes. GCCGnCGC has been reported as a
SMAD1 binding motif (Benchabane and Wrana, 2003; Ishida, et al., 2000; Kim, et
al., 1997; Kusanagi, et al., 2000). Kusanagi, et. al. (2000) provided evidence that
a reporter gene construct containing multiple copies of this motif was stimulated
in response to BMP, but not in response to TGFβ or activin. It has also
previously been reported that SMAD1 binds to this sequence in the SMAD7
promoter (Benchabane et al., 2003).
GTCTAGAC has been shown to be a SMAD5 binding sequence (Li, et al.,
2001; Zawel, et al., 1998) and has also been reported to be TGFβ-responsive
(Stopa, et al., 2000). The CAGACA motif is also not specific to BMP-activated
SMADs. It has been reported to be BMP-responsive in the ID1 promoter, and
both SMAD4 and SMAD1 can bind this sequence (Katagiri, et al., 2002). This
element was also identified in the promoter of JunB, and expression of JunB was
induced by TGFβ, activin, and BMP (Jonk, et al., 1998). However, Dennler et al.
(1998) reported that this sequence was specific to TGFβ and activin responses.
Several other TGFβ response sequences have been reported. Song et al.
(1998) reported that both SMAD3 and SMAD4 bind to the motif
AGACAAGGTTGT in the promoter of human type 1 plasminogen activator
inhibitor (PAI1), and activate transcription in response to TGFβ.
ACAGACAGACAC has been identified as a binding site for the SMAD3-SMAD4
complex in the promoter of JunB and is TGFβ responsive (Wong 1999).
Additionally TGFβ has been shown to enhance the expression of type VII
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collagen (COL7A1) by inducing the binding of the SMAD3-SMAD4 complex to
the sequence, GCCCACCAGACAGATGGCTGAATCACAGGAGTGGCCGGCG
GGACCCATGGCCT within the promoter of COL7A1 (Kon et al., 1999,
Vindevoghel et al., 1998). Hua et al. (1998, 1999) identified two sequences in
the PAI1 promoter that contained multiple AGAC SMAD-binding element repeats,
AGACAGACAAAACCTAGACAATCACGTGGCTGGCTGCATGCCCTGTGGCTG
TTGGGC and CCTAGACAGACAAAACCTAGACAATCACGTGGCTGG; these
sequences also contain a binding site for transcription factor µE3 (TFE3), which
was determined to be an essential binding partner in the SMAD transcriptional
complex for TGFβ-induced transcription of PAI1 (Hua et al., 1999). Lindemann
et al. (2001) described a TGFβ-responsive SMAD3-SMAD4 binding element in
the promoter of parathyroid hormone-related protein (PTHrP), GAGGAGGTAGA
CAGACAGCTATGT, which aso contained multiple AGAC SMAD-binding
element repeats, as well as an Ets transcription factor binding domain. Finally,
Shi et al. (1998) performed cocrystallization studies and electrophoretic mobility
shift assays to identify a the SMAD3 DNA binding element, AGTATGTCTAGAC
TGA.
Using the Motif Locator tool on the MOtif Discovery (MoD) tools website
(http://159.149.109.9/modtools/; Pavesi 2006), the promoter sequences of
specific genes, chosen based on our microarray analysis and previous reports
associating these genes with metastasis, migration, or TGF superfamily
signaling, were searched for the presence of each of the SMAD binding elements
(Table 3.7). ADAMTS1, CXCR4, LEFTY1, SMAD7, MAP3K7, and WNT3 were
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all upregulated in SKI knockdown cells according to our microarray data. CXCR4,
SMAD7, and WNT3 promoters contained all three of the BMP response elements.
CXCR4 and SMAD7 both contained multiple copies of each of the three BMP
response elements, and it has been reported that multiple copies of the
consensus sequence promotes SMAD binding (Ishida, et al., 2000; Kusanagi, et
al., 2000). The WNT3 promoter had multiple copies of the two motifs that are not
BMP-specific, and only one copy of the GCCGnCGC motif. The MAP3K7
promoter contained multiple copies of the BMP-specific motif and the nonspecific motif, CAGACA. The ADAMTS1 promoter contained multiple copies
both the GTCTAGAC and the CAGACA motif; these two motifs are responsive to
both TGFβ and BMP. The LEFTY1 promoter contained multiple copies of the
TGFβ/BMP-response element CAGACA motif as well as multiple copies of the
BMP-specific GCCGnCGC motif. The ADAMTS1 promoter was the only
promoter that contained TGFβ-specific response element, the ACAGACAGACAC
motif.
FST (follistatin) and SPARC (secreted protein acidic and rich in cysteine)
were both downregulated in SKI knockdown cells compared to control cells. The
FST promoter contained multiple copies of both of the TGFβ/BMP response
motifs as well as the BMP-specific motif. The SPARC promoter also contained
multiple copies of both of the TGFβ/BMP response motifs, but the BMP-specific
motif was not present.
SMAD6 was not differentially expressed in shSKI compared to shNC
NCCIT cells according to our microarray data; however its expression has
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Table 3.7. SMAD Promoter Elements in Potential Target Genes.

BMP
Elements

GTCTAGAC*
CAGACA**

TGFβ
Elements

ADAMTS1
+ (2)

CXCR4
+ (4)

FST
+ (6)

LEFTY1
-

MAP3K7
-

MMP9
+ (6)

SMAD6
+ (2)

SMAD7
+ (4)

SPARC
+ (6)

WNT3
+ (2)

+ (66)

+ (79)

+ (72)

+ (113)

+ (92)

+ (69)

+ (84)

+ (66)

+ (78)

+ (30)

GCCGnCGC

-

+ (13)

+ (63)

+ (29)

+ (2)

-

+ (71)

+ (2)

-

+ (1)

GTCTAGAC*

+ (2)

+ (4)

+ (6)

-

-

+ (6)

+ (2)

+ (4)

+ (6)

+ (2)

+ (69)
+ (1)
-

+ (84)
-

+ (66)
-

+ (78)
-

+ (30)
-

+ (66)
-

+ (79)
-

+ (72)
-

+ (113)
-

+ (92)
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

AG(C/A)CAGACA**
AGACAAGGTTGT
ACAGACAGACAC
GCCCACCAGACA
GATGGCTGAATCA
CAGGAGTGGCCG
GCGGGACCCATG
GCCT
AGACAGACAAAAC
CTAGACAATCACG
TGGCTGGCTGCAT
GCCCTGTGGCTG
TTGGGC
CCTAGACAGACAA
AACCTAGACAATC
ACGTGGCTGG
GAGGAGGTAGAC
AGACAGCTATGT
AGTATGTCTAGAC
TGA

* and ** sequences have been described to be both BMP and TGFβ responsive. + indicates the response element was present in
the promoter sequence; - indicates the response element was not present. Numbers in ( ) indicate the number of times the response
element was detected within the promoter sequence.
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previously been described to be regulated by BMP (Ishida, et al., 2000), and thus
served as a positive control. The SMAD6 promoter contained multiple copies of
both of the TGFβ/BMP response motifs and the BMP-specific motif. MMP9 is a
matrix remodeling protein, and, thus, thought to be involved in metastasis.
MMP9 also was not differentially expressed in shSKI compared to shNC NCCIT
cells according to our microarray data, and, therefore, appears to be SKI nonresponsive. However, it also contained multiple copies of the BMP-specific motif
as well as multiple copies of the TGFβ/BMP response motif, CAGACA.

SDF/CXCR4: Role in invasion of SKI-knockdown cells
According to the microarray data, CXCR4 mRNA expression was
upregulated in shSKI NCCIT cells compared to shNC NCCIT cells. CXCR4 and
its signaling ligand, SDF1, have previously been implicated in metastasis, and
are also important regulators of germ cell migration. Therefore, we sought to
determine if this upregulation of CXCR4 contributes to the increased invasive
potential seen in SKI-knockdown NCCIT cells.
The microarray results that CXCR4 mRNA is upregulated in shSKI NCCIT
cells compared to shNC NCCIT cells were first confirmed using real time PCR
analysis (Figure 3.14). CXCR4 is, indeed, upregulated 5.5 fold in shSKI NCCIT
cells compared to shNC cells, however, addition of BMP or its inhibitor, noggin,
did not significantly alter the levels of CXCR4 mRNA in either shSKI or shNC
NCCIT cells. SDF1, the signaling ligand partner of CXCR4, has previously been
shown to be upregulated by BMP (Yang, et al., 2008). However, at the
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concentration used, real time PCR showed no change in SDF1 mRNA
expression in response to treatment of either shNC or shSKI NCCIT cells with
BMP4 (Figure 3.15). This indicates that, at the concentrations used, BMP is not
able to induce transcription of CXCR4 or SDF1 in either shNC or shSKI NCCIT
cells.
Since CXCR4 is increased in shSKI NCCIT cells compared to shNC
NCCIT cells, Matrigel invasion assays were used to assess whether this
upregulation of CXCR4 enhanced the invasive phenotype of the shSKI NCCIT
cells. SDF1, the signaling ligand for CXCR4, and/or AMD3100, a potent and
specific inhibitor of CXCR4 (Broxmeyer, et al., 2005; Hatse, et al., 2002), were
added to the companion wells of the Matrigel invasion chambers to determine
their effects on the invading cells. Addition of 25 ng/mL SDF1 to the companion
wells significantly increased the invasion of shSKI NCCIT cells, but had no effect
on the invasion of shNC NCCIT cells (Figure 3.16). When 50 ng/mL AMD3100
was added in combination with SDF1, it was able to significantly reduce the
effects of SDF1, almost to the level of invasion seen in shNC NCCIT cells (Figure
3.16). Addition of 50 ng/mL AMD3100 alone significantly reduced the level of
invasion in shSKI NCCIT cells to the level of invasion seen in shNC NCCIT cells.
However, addition of AMD3100 to shNC NCCIT cells did not affect invasion of
these cells, indicating that AMD3100, alone, does not affect invasion. These
data suggest that the CXCR4/SDF1 signaling partners enhance the invasive
phenotype of NCCIT cells with reduced levels of SKI.
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Figure 3.14. CXCR4 mRNA expression in shNCCIT cells treated with BMP and/or
noggin. Real time PCR analysis comparing CXCR4 mRNA expression in shNC NCCIT
cells ± 10ng/mL BMP, ± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL
BMP, ± 0.1µg/mL noggin. RNA levels were normalized to 18S RNA. Data represents
three individual trials and was analyzed using 2-∆∆Ct method; error bars indicate the 95%
confidence interval.
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Figure 3.15. SDF1 mRNA expression in shNCCIT cells treated with BMP and/or
noggin. Real time PCR analysis for SDF1 mRNA in shNC NCCIT cells ± 10ng/mL BMP,
± 0.1µg/mL noggin compared to shSKI NCCIT cells ± 10ng/mL BMP, ± 0.1µg/mL noggin.
RNA levels were normalized to 18S RNA. Data represents three individual trials and
was analyzed using 2-∆∆Ct method; error bars indicate the 95% confidence interval.
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Figure 3.16. Role of CXCR4/SDF1 in the invasive potential of shNCCIT cells. Bar
graph representing the number of migrating cells in Matrigel invasion assays using shNC
NCCIT cells and shSKI NCCIT cells ± 25ng/mL SDF, ± 50ng/mL AMD 3100 to the
medium in the companion wells. Data represents five trials; error bars indicate SEM;
Groups labeled A, B, and C, and D are each significantly different from each other with p
< 0.05.
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CHAPTER IV

DISCUSSION

SKI has previously been described as an oncogene based on its ability to
transform avian fibroblasts (Colmenares and Stavnezer, 1989). However, the
role of SKI in mammalian tumorigenesis is not yet fully characterized. The
available literature on SKI suggests that SKI plays dual roles in tumorigenesis
and that SKI’s involvement in cancer progression may be cell type and context
dependent. For example, SKI has been shown to promote proliferation in
pancreatic cancer cells (Heider, et al., 2007), yet other studies have shown that
SKI does not affect the rate of proliferation in lung and breast cancer cell lines
(Le Scolan, et al., 2008; Zhu, et al., 2007). In addition, various studies have
shown that SKI is over-expressed in some tumor types including melanoma,
esophageal, colon, and pancreatic cancer (Buess, et al., 2004; Fukuchi, et al.,
2004; Heider, et al., 2007; Reed, et al., 2005). In contrast, data presented by
Shinagawa et. al.(2001), showed that mice heterozygous for a null mutation in
the SKI gene were more susceptible to tumorigenesis, which suggests that SKI
may function as a tumor suppressor.
The data presented within this text supports the idea that SKI may play
different roles in tumorigenesis in different cell types. Analysis of a panel of
human cell lines for SKI expression showed that SKI expression varies widely in
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different types of cancer. In support of previous data (Reed, et al., 2005), SKI
expression increases in progressing stages of melanoma, with the highest
expression seen in WM9 metastatic melanoma cells. On the other hand, SKI
expression appears to be lower in T47D ductal carcinoma cells compared to
HMEC normal breast cells; while the level of SKI expression in MCF7 mammary
adenocarcinoma cells was very similar to that of HMEC cells. Both of these cell
lines were derived from metastatic pleural effusions, and are described as weakly
metastatic in vitro (Lacroix and Leclercq, 2004). HCT116 cells, derived from a
primary colorectal carcinoma (Brattain, et al., 1981), expressed high levels of SKI,
while A549 primary lung carcinoma cells have very low SKI expression. The
level of SKI expression in NCCIT embryonal carcinoma cells, derived from a
mediastinal metastasis, was intermediate compared to other cell lines studied.
Taken together, these data indicate that SKI may, indeed, act as an oncogene in
some tissues, but may play an anti-tumorigenic role in others.
The data presented here indicate that SKI expression is decreased in
human testicular germ cell tumors compared to normal testis samples. Previous
studies have shown that CCND2 mRNA and protein expression are increased in
TGCT samples compared to normal testis (Bartkova, et al., 1999; Houldsworth,
et al., 1997; Schmidt, et al., 2001). Our real time PCR data confirms this
observation, and CCND2 served as a positive control in these experiments. SKI
mRNA expression decreased in the same tumor samples, while SNO was not
differentially expressed. Furthermore, our data also show that proliferation is not
affected by SKI expression in NCCIT testicular cancer cells. However, the level
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of SKI expression in NCCIT cells does influence the ability of these cells to
migrate and invade since experimentally reducing SKI expression in NCCIT cells
resulted in increased invasive potential. These data suggest that in testicular
germ cell tumors SKI does not act as an oncogene, but rather promotes tumor
progression to a metastatic state.
SKI has been identified as a negative regulator of the TGFβ superfamily.
Previous data indicate that TGFβ has diverging roles in tumorigenesis. While
TGFβ may act as a tumor suppressor in the early stages of tumorigenesis by
inhibiting cellular proliferation, evidence suggests that TGFβ superfamily
signaling promotes cancer invasion and metastasis, permitting cancer
progression (Derynck, et al., 2001; Le Scolan, et al., 2008; Leivonen and Kahari,
2007; Rothhammer, et al., 2005; Tang, et al., 2003; Wakefield and Roberts, 2002;
Zhu, et al., 2007). A recent study reported that forced over-expression of SKI in
JygMC(A) mouse mammary carcinoma cells decreased the metastatic potential
of these cells in vivo (Azuma, et al., 2005). In accordance with this finding, Le
Scolan et al. (2008) recently reported that experimentally reducing SKI
expression in breast and lung cancer cell lines promoted TGFβ-mediated cancer
metastasis. Similarly, we found that reducing SKI expression in NCCIT testicular
cancer cells resulted in a more invasive phenotype. In the same study by Le
Scolan et. al. (2008), they found that SKI was abundantly expressed in a panel of
metastatic melanoma cells and breast cancer cell lines. We also found that SKI
expression is high in metastatic melanoma and variable in other cell lines derived
from metastatic and primary tumors. These data suggest that the role of SKI in
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tumorigenesis is complex and may be dependent on the tissue type and other
factors present within the cell and microenvironment as well as the levels of SKI.
The data presented in this body of work support the role of SKI as an
inhibitor of metastasis in TGCTs. In human embryonal carcinoma NCCIT cells,
decreasing the expression of SKI resulted in enhanced migration and invasion,
while forcing the expression of SKI significantly reduced the invasive potential of
these cells, as assessed by both cell scrape assays and Matrigel invasion assays.
Interestingly, it has also been reported that experimentally reducing SNO,
another member of the SKI gene family, in breast and lung cancer cell lines
resulted in increased metastatic potential in these cells in response to TGF (Zhu,
et al., 2007). In contrast to reduced SKI levels in TGCTs, our data show that
SNO expression was not significantly different in TGCTs and normal testis
samples, indicating that SKI, but not SNO, may be involved in testicular cancer
progression and metastasis. These data, taken together with the tumor data
showing decreased SKI expression in human TGCTs, suggest that SKI may
function to prevent testicular cancer metastasis by repressing signals from the
TGFβ superfamily.
In the current experiments, decreased SKI expression was sufficient to
promote invasion in the testicular cancer cell lines without the addition of growth
factors, suggesting that the cells may be responding to an autocrine loop of
TGFβ superfamily signaling. Although the SKI-knockdown cells were cultured in
low-serum medium, it is also possible that factors in the serum may contribute to
the increased metastasis observed in these studies. In addition to being a co-
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repressor of the TGFβ superfamily, SKI is able to interact with transcription
factors other than SMADs, including MyoD (Engert, et al., 1995) and nuclear
factor I (NF1) (Tarapore, et al., 1997), and therefore, the increase in invasive
potential seen in SKI-deficient cells could also partially be due to changes in
gene expression that are independent of TGFβ superfamily signaling.
It is possible that the level of closure observed in the cell scrape assays
could be due in part to proliferation of the cells at the border of the scrape;
however, it is unlikely that the closure could be due to proliferation alone. The
rate of proliferation in the SKI-knockdown cells was not significantly different from
that of the control treated cells. The NCCIT cells have a population doubling time
of approximately 18 hours (data not shown). Migration was observed over a 20
hour time period, thus the NCCIT cells barely had time to complete one round of
division. In the cell scrape assays, the distance that cells have migrated into the
scrape area is greater than one cell diameter in thickness at 20 hours compared
to the scrape at 0 hours. Furthermore, the data from the cell scrape assays are
complemented by the Matrigel invasion assays, which require cells to migrate
through a membrane coated with Matrigel. Therefore, cellular proliferation cannot
fully account for the percentage closure observed.
There is further evidence to suggest that TGFβ superfamily signaling
molecules may be involved in metastasis of testicular cancer. The TGFβ
superfamily has been implicated in the allocation and migration of primordial
germ cells (PGCs), the precursors to adult germ cells, during development.
BMP4 and BMP8b, members of the TGFβ superfamily, have been shown to be
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required for the allocation of PGCs in the mouse and also appear to be involved
in PGC migration (Dudley, et al., 2007; Lawson, et al., 1999; Pesce, et al., 2002;
Ying, et al., 2000; Ying, et al., 2001). Additionally, TGFβ1 has a chemotropic
affect on PGCs, and, thus, may be involved in germ cell migration (Godin and
Wylie, 1991). This suggests that loss of function of SKI may contribute to the
metastasis of testicular cancer by allowing uncontrolled signaling from the TGFβ
superfamily, which may function to increase the migration of TGCTs through a
chemotropic effect, promoting the dissemination of tumor cells. It has been
proposed that testicular cancer metastasis is related to the migration process of
PGCs, partially based on common sites of metastasis being related to the path of
migrating PGCs (Chaganti, et al., 1994). Thus genes involved in PGC migration
are of interest as potential target genes promoting testicular cancer metastasis.
The data presented within text show that decreased SKI expression
appears to promote a more invasive phenotype in NCCIT cells. Since SKI is
known to be a co-repressor of the TGFβ superfamily, the next goal of this
research was to determine if loss of function of SKI contributes to testicular
cancer metastasis by allowing uncontrolled signaling from the TGFβ superfamily.
To address this question, we studied the response of SKI- knockdown NCCIT
cells to both TGFβ and BMP to determine if these members of the TGFβ
superfamily further enhanced the increased invasive potential seen in NCCIT
cells with reduced SKI expression.
TGFβ has been shown to promote metastasis in the later stages of some
cancers (Jakowlew, 2006; Tang, et al., 2003). Le Scolan et. al. (2008) reported
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that SKI plays an antitumorigenic role in MDA-MB-231 breast cancer cells and
A549 lung cancer cells. Expression of SKI was high in MDA-MB-231 breast
cancer cells and low in A549 lung cancer cells. Experimentally reducing levels of
SKI in these cells resulted in an enhanced ability of these cells to invade.
Furthermore, they found that treating these cells with TGFβ reduced SKI
expression through E3 ubiquitin ligase-mediated degradation, and they suggest
that this pathway plays an important role in the ability of SKI to repress
metastasis. Taken together, these data suggest that reduced levels of SKI in
cancer cells may promote metastasis by allowing unregulated signaling of TGFβ.
However, our data shows that addition of TGFβ to shSKI NCCIT cells did not
affect the migration of these cells in vitro. Furthermore, the addition of TGFβ
blocking antibody also did not affect the migration of shSKI NCCIT cells. This
indicates that in NCCIT cells with reduced SKI expression, TGFβ does not affect
migration.
There are several possible reasons to explain why TGFβ may not have an
effect on the migration of SKI-deficient NCCIT cells. One possible explanation is
that the components of the TGFβ signaling pathway are not present or are not
active in NCCIT cells. This prompted us to look at the activity of the TGFβ
pathway in these cells by investigating SMAD phosphorylation. TGFβ signals
through intracellular transcription factors, SMAD2 and SMAD3. When TGFβ
activates the cell surface receptors, these receptors induce the phosphorylation
of SMAD2 and SMAD3, which then form a complex with SMAD4. This complex
is able to translocate to the nucleus and activate transcription of TGFβ target
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genes (Luo, 2003). Western blots showed that SMAD2 is expressed in shNCCIT
cells. However, even after a two hour incubation with TGFβ, phosphorylated
SMAD2 (p-SMAD2) was only detected at very low levels. Based on microarray
data, ELISA, and Superarray PCR data (data not shown) other components of
the TGFβ signaling pathway, including TGFβ receptors and TGFβ, are expressed
in NCCIT cells. Treatment with TGFβ did result in a slight induction of p-SMAD2.
However, because this induction was only slight, it is possible that an inhibitor of
TGFβ may be preventing strong signaling from this pathway, even in the absence
of SKI.
LEFTY1 is an inhibitor of the TGFβ superfamily which functions by
preventing SMAD phosphorylation (Ulloa, et al., 2001). LEFTY1 was shown via
the microarray analysis, and confirmed by real time PCR analysis, to be
upregulated in shSKI NCCIT cells compared to shNC NCCIT cells. Increased
LEFTY1 expression may contribute to the lack of response seen in shSKI NCCIT
cells treated with TGFβ. TGIF, which interacts with SMAD2 and SMAD3 to
prevent TGFβ signaling, was also shown to be expressed in shSKI NCCIT cells
by Superarray PCR analysis (data not shown). In addition, the inhibitory SMAD,
SMAD7, was also increased in shSKI NCCIT cells compared to shNC NCCIT
cells according to microarray analysis. Although SMAD7 has been shown to
interfere with both TGFβ and BMP signaling, there may be multiple inhibitors
acting against TGFβ signaling that weaken that branch of the TGFβ superfamily
while allowing BMP signaling. Finally, our data showed that SKI mRNA
expression is decreased in TGCTs compared to normal testis samples, but SNO
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mRNA levels were not altered. Both SKI and SNO have been shown to repress
TGFβ signaling (Akiyoshi, et al., 1999; Luo, et al., 1999), but only SKI has been
shown to interfere with BMP signal transduction (Takeda, et al., 2004; Wang, et
al., 2000). This suggests that SNO may also function to inhibit TGFβ signaling,
even in the absence of SKI, but BMP signaling could still be active.
In addition to inhibiting TGFβ signaling, SKI also functions as a corepressor of BMP, another member of the TGFβ superfamily, through its
interaction with SMAD1/5/8 – SMAD4 complex (Takeda, et al., 2004; Wang, et al.,
2000). Therefore, we next tested the effect of adding BMP to our cell scrape
assays to determine if this enhanced migration in SKI knockdown NCCIT cells.
When exogenous BMP4 was added to cell scrape assays, migration was
significantly increased in shSKI NCCIT cells, but not in shNC NCCIT cells.
Furthermore, addition of noggin, an extracellular BMP inhibitor, was able to
reverse the effects of BMP seen in shSKI cells, and addition of noggin alone
reduced migration in shSKI NCCIT cells back to the level of migration seen in
untreated shNC NCCIT cells. Noggin treatment, alone, also slightly reduced
migration in shNC NCCIT cells. This suggests that treating both shSKI and
shNC NCCIT cells with noggin may inhibit the effects of any endogenous BMP
expressed by NCCIT cells. This data indicates that reduced levels of SKI in
NCCIT cells enhance the migration of these cells by allowing increased BMP
signaling.
The activity of the BMP pathway was also considered by testing the cells
for the induction of phosphorylated R-SMADs. BMP signals are transmitted
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intracellularly by SMADs 1, 5, and 8 (Yamashita, et al., 1996). Activation of cell
surface receptors by BMP results in phosphorylation of SMAD1/5/8, which then
forms a complex with SMAD4, and this complex activates the transcription of
BMP target genes. ShSKI and shNC NCCIT cells incubated with BMP4 for two
hours showed strong expression of phospho-SMAD1/5/8 (p-SMAD1/5/8).
Phosphorylation of SMAD1/5/8 was inhibited in the presence of noggin. This
indicates that the BMP pathway is active in shNCCIT cells. As expected,
phosphorylation of SMAD1/5/8 was not affected by SKI expression because
SKI’s inhibition of BMP signaling acts downstream of SMAD phosphorylation.
The data collected on the effects of BMP in SKI-deficient NCCIT cells suggest
that the BMP family may be a potential target to consider in the development of
new therapies to treat patients with metastatic testicular cancer. However,
further research is necessary to determine the efficacy of using BMP inhibitors to
prevent testicular cancer metastasis in vivo.
Because SKI functions primarily as a transcription factor and co-repressor,
microarray analysis was performed to identify potential target genes with altered
expression in SKI-deficient cells that may contribute to an invasive phenotype
and play a role in testicular cancer progression. As expected, one of the gene
sets identified through microarray analysis by GSEA as being upregulated in SKIknockdown cells compared to control cells was the “Transforming Growth Factor
Beta Receptor Signaling Pathway” (Table 3.3). Several genes involved in TGFβ
superfamily signaling were also identified by SAM analysis as being differentially
expressed in shSKI NCCIT cells compared to shNC NCCIT cells (Table 3.6).
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SKI is a co-repressor of the TGFβ superfamily, therefore, it would be expected
that some members of this signaling pathway would be affected by depleting SKI.
In studying the results from the GSEA and SAM analyses, some common genes
were identified as being upregulated in SKI-knockdown NCCIT cells, including
SMAD7, LEFTY1, and MAP3K7. As previously discussed, SMAD7 and LEFTY1
are both inhibitors of TGFβ signaling, thus increased expression of these genes
may contribute to the lack of response seen with the addition of TGFβ to shSKI
NCCIT cells in the cell scrape migration assays.
“Regulation of MAP kinase activity” was one of only three gene sets
identified by GSEA that met not only the dual criteria of FDR less than 0.25 and
nominal p-value less than 0.05, but also the more stringent test of FWER less
than 0.05. Interaction between the MAPK and BMP pathways has previously
been shown to be involved in cell fate determination. FGF8 and IGF2, both of
which activate MAPK signaling, have been shown to inhibit nuclear localization of
the BMP-responsive SMAD1; this interaction can function to inhibit BMP
signaling, preventing differentiation down the mesoderm lineage and favoring
neural differentiation (Massague, 2003). However, these specific genes were not
identified through GSEA as being enriched in the SKI-knockdown cells. Since
MAPK signaling can function to inhibit SMAD1-mediated transcription by blocking
nuclear localization of SMAD1, it is possible that upregulation of MAPK signaling
may be a compensation mechanism for the increased activity of the BMP
pathway in SKI-knockdown cells. Activation of the Ras/MAPK pathway has also
been shown to inhibit SMAD2 nuclear localization, preventing TGFβ signaling
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(Massague, 2003). This suggests that upregulation of MAPK signaling in SKIknockdown cells may contribute to the lack of response seen with the addition of
TGFβ to the shSKI NCCIT cells. A specific link between SKI and the MAPK
pathway has not been shown. Thus our data suggest that there may be further
interaction between MAPK signaling and TGFβ superfamily signaling.
One of the genes identified by GSEA as belonging to the gene group
“Regulation of MAP kinase activity” was CXCR4. CXCR4 was also shown to be
upregulated by SAM analysis in shSKI NCCIT cells compared to shNC NCCIT
cells, and this increased expression was confirmed via real time PCR.
CXCR4/SDF1 signaling partners have previously been shown to be involved in
both PGC migration (Doitsidou, et al., 2002; Molyneaux, et al., 2003) and
testicular cancer metastasis (Gilbert, et al., 2009); SDF1 acts as a
chemoattractant for the germ cells and cancer cells, which express CXCR4.
SDF1 is known to be expressed in sites of the body to which testicular cancer
frequently metastasizes, including lymph nodes, lung, liver, and brain (Gilbert, et
al., 2009; Muller, et al., 2001), further implicating these signaling partners as
potential mediators of testicular cancer metastasis.
We were interested to know if CXCR4 is a possible target of BMP
signaling. Real time PCR analysis showed that, at the concentration used,
CXCR4 expression was not significantly changed when shNC or shSKI NCCIT
cells were incubated with either BMP or noggin. These data suggest that the
increase in CXCR4 expression in shSKI NCCIT cells compared to shNC NCCIT
cells may be independent of BMP signaling. SDF1, the signaling ligand partner
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of CXCR4, has previously been shown to be upregulated by BMP (Yang, et al.,
2008). However, at the concentration used, real time PCR showed no change in
SDF1 mRNA expression in response to treatment of either shNC or shSKI
NCCIT cells with BMP4.
Although CXCR4 and SDF1 expression were not affected by BMP4
treatment of shNCCIT cells, CXCR4 expression was upregulated in SKIknockdown NCCIT cells compared to NCCIT cells stably transfected with the
negative control shRNA vector. Thus, the effect of SDF1 on the ability of these
cells to invade in vitro was tested using a Matrigel invasion assay. Addition of
SDF1 to the companion wells of the Matrigel invasion chambers significantly
enhanced the invasion of shSKI NCCIT cells but had no effect on shNC NCCIT
cells. Furthermore, AMD3100, a potent and specific inhibitor of CXCR4
(Broxmeyer, et al., 2005; Hatse, et al., 2002), was able to reverse the effects of
SDF1 in shSKI NCCIT cells, but, again, no effect was seen in shNC NCCIT cells.
These data provides good evidence that increased expression of CXCR4 in SKIknockdown NCCIT cells contributes to the enhanced invasive phenotype seen in
these cells.
Previous data have implicated the CXCR4/SDF1 signaling partners in
testicular cancer metastasis (Gilbert, et al., 2009). Our data support the role of
CXCR4/SDF1 signaling in testicular cancer metastasis, and our data also adds
additional information on the upstream regulation of CXCR4 expression, which
gives a better overall picture of the mechanism by which testicular cancer cells
may acquire a more invasive phenotype. These data, taken together with
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previous data showing that BMP also enhances migration in shSKI NCCIT cells,
suggests that decreased SKI expression in NCCIT testicular cancer cells
promotes migration and invasion through both BMP-dependent and BMPindependent pathways. This collection of data also implicates CXCR4 and SDF1
as potential targets for testicular cancer therapies. Again, further research is
needed to determine the effects of using inhibitors CXCR4 and SDF1 signaling in
vivo.
Several genes belonging to the WNT signaling family were identified by
SAM analysis as being differentially expressed in shSKI compared to shNC
NCCIT cells. Interaction between SKI and the WNT family has previously been
shown (Chen, et al., 2003). In melanoma cells, forcing the expression of SKI
stimulated cellular proliferation by activating the WNT pathway. Chen et. al.
(2003) found that SKI binds to FHL2 (four-and-a-half lim domains 2), which binds
β-catenin and can either repress or activate β-catenin, depending upon the cell
type (Martin, et al., 2002). Forced SKI expression resulted in the activation of
FHL2 and β-catenin-responsive gene promoters. These data suggest that, in
addition to mediating TGFβ superfamily target gene transcription, SKI can act as
a transcriptional regulator of the WNT signaling family by acting as a binding
partner for FHL2. This could be a BMP-independent mechanism for gene
regulation in our system which merits further exploration.
While several individual genes and gene families of interest were identified
as potential participants in testicular cancer metastasis by microarray analysis,
there are some notable absences in groups of genes that one might expect to be
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involved in the observed invasive phenotype. For example, GSEA did not reveal
significant differences in gene sets such as “Cell migration” and “Cell-cell
adhesion”; nor were there any significant changes in matrix metalloproteinases
(MMPs). Genes in these groups would likely be involved in invasion and
metastasis, so one might expect these sets to be significantly altered in the
shSKI NCCIT cells, which had enhanced invasive potential. There are several
possible explanations for the absence of a significant difference in these gene
sets. (1) There are limitations in the GSEA software in that it is not yet capable
of identifying significant changes in gene sets that have both up- and downregulated genes. The software currently only recognizes significantly upregulated genes. It is quite possible that certain genes involved in the prevention
of cellular migration, for example, may be down-regulated in SKI-knockdown
cells, contributing to the enhanced invasive phenotype. However, these changes,
though potentially important to the observed phenotype, would not be recognized
by GSEA. (2) The gene sets used in this software are constructed based on the
available literature. They are not all-inclusive, and it is possible that there are
additional genes involved in cellular migration or cell-cell adhesion that are not
represented in the GSEA gene sets, but that may be important in promoting
invasion in NCCIT cells. (3) GSEA considers the gene set as a whole entity.
While several members of the gene set may not be significantly enhanced, there
still may be a few members of that gene set that are significantly altered in the
shSKI NCCIT cells. (4) The absence of significant changes in groups of genes
such as MMPs may be explained by the fact that these genes may not be
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transcriptionally regulated by SKI, but could possibly be altered at the level of
protein activity. MMPs are made as propeptides and require cleavage for
activation (Fanjul-Fernandez, et al., 2009). It is possible that decreased SKI
expression my lead to the transcription of certain genes that promote the
eventual cleavage and activation of MMPs. Further studies could be performed
to determine if the activity of certain MMPs is increased in SKI-knockdown
NCCIT cells to assess whether the activation of MMPs plays a role in the
enhanced invasive phenotype observed in SKI-deficient NCCIT cells. These
studies involve exposing the cells to gels containing the specific substrate for a
particular MMP, and measuring the breakdown of that substrate.
Although MMP expression was not significantly changed in shSKI
compared to shNC NCCIT cells, the microarray data did show an increase in
ADAMTS1, a metalloproteinase from another gene family, in shSKI NCCIT cells
compared to shNC NCCIT cells, which was confirmed by real time PCR.
ADAMTS1 is a member of the ADAMTS (A Disintegrin And Metalloproteinase
with ThromboSpondin repeats) family. This gene family is involved in proteolytic
processing of transmembrane proteins, cell adhesion, and cell signaling
(Mochizuki and Okada, 2007). ADAMTS1 has been shown to be upregulated in
cancers with advanced metastatic potential, including breast cancer (Kang, et al.,
2003) and pancreatic cancer (Masui, et al., 2001). It has also been reported that
ADAMTS1 forced overexpression in human lung carcinoma cells promotes tumor
development and enhances tumor cell proliferation after injection in into SCID
mice (Rocks, et al., 2008). These data imply that increased ADAMTS1
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expression may promote cancer progression. However, more research is
necessary to determine if ADAMTS1 expression is regulated by SKI and to
delineate the role of ADAMTS1 in testicular cancer.
The microarray data revealed several genes and gene families that are
potential targets of SKI and/or may be involved in an enhanced metastatic
phenotype in testicular cancer. From the list of genes generated by the
microarray analysis, a subset of genes associated with invasion, migration, or
TGF superfamily signaling was chosen to assess whether their promoters
contained SMAD binding elements. These genes include ADAMTS1, CXCR4,
FST, LEFTY1, MAP3K7, SMAD7, SPARC, and WNT3. In addition, SMAD6 and
MMP9 were used as controls. The purpose of this assessment was to determine
if these genes might be downstream signaling targets of either BMP or TGFβ.
The presence of a SMAD binding element within the promoter region of these
genes would indicate that the gene may be transcriptionally activated by BMP or
TGFβ. Although no true SMAD consensus sequence has yet emerged, a
literature search revealed several potential SMAD 2/3 and SMAD1/5/8 binding
sequences. Genes containing binding sites for SMAD2/3 within their promoter
region would potentially be activated in response to TGFβ signaling, while genes
containing SMAD1/5/8 binding sites would potentially be activated by BMP.
Since BMP treatment of SKI-knockdown cells resulted in an enhanced
invasive phenotype, but TGFβ treatment did not elicit a response, we were
interested in comparing the presence of BMP and TGFβ response elements in
potential target genes identified through the microarray analysis. The literature
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search revealed that there is some overlap in the sequences that have been
designated as BMP and TGFβ responsive. In this analysis, three BMP-response
elements and eight TGFβ-response elements were used. However, 2 of the
sequences, GTCTAGAC (Li, et al., 2001; Stopa, et al., 2000; Zawel, et al., 1998)
and CAGACA (Dennler, et al., 1998; Jonk, et al., 1998; Katagiri, et al., 2002),
have been described in the literature as being both BMP and TGFβ responsive.
It was also reported that SMAD4 is able to bind to the sequence GTCTAGAC in
the promoter of ID1 (Katagiri, et al., 2002), and this provides an explanation for
the lack of specificity in regards to BMP and TGFβ responsiveness. SMAD4 acts
as the co-SMAD; it is able to form a complex with either BMP-induced
SMAD1/5/8 or TGFβ-induced SMAD2/3 (Luo, 2003). Therefore if the sequence
GTCTAGAC is recognized by SMAD4, expression of genes with this element in
their promoter could be activated by either BMP or TGFβ or both. The third
sequence, GCCGnCGC, has thus far been described to be specific to the BMPresponsive SMADS (Benchabane and Wrana, 2003; Ishida, et al., 2000; Kim, et
al., 1997; Kusanagi, et al., 2000).
For the promoter analysis, SMAD6 was used as a positive control.
SMAD6 was not differentially expressed in shSKI and shNC NCCIT cells,
however, it has been reported that SMAD6 is BMP-responsive and contains the
SMAD1 binding motif, GCCGnCGC (Ishida, et al., 2000). The current analysis
found the presence of multiple copies of the GCCGnCGC binding motif, as well
as multiple copies of the two other BMP/TGFβ response elements, CAGACA and
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GTCTAGAC. This shows that the Motif locator tool was capable of recognizing
the sequences.
ADAMTS1, CXCR4, LEFTY1, SMAD7, MAP3K7, and WNT3 were all
upregulated in SKI knockdown cells according to our microarray data. CXCR4,
SMAD7, and WNT3 promoters each contained all three of the BMP response
elements, including the BMP-specific response element. This suggests that their
up-regulation in shSKI NCCIT cells may be due to increased BMP signaling. In
agreement with these data, SMAD7 has previously been shown to be responsive
to BMP (Benchabane and Wrana, 2003). Although CXCR4 does appear to
contain these BMP response elements, the real time PCR data presented in this
text (Figure 3.14) did not show up-regulation of CXCR4 in response to treatment
of shSKI NCCIT cells with BMP4. It is possible that the concentration of BMP4
used in these experiments was not sufficient to induce transcription of CXCR4,
and further experiments are needed to determine if different concentrations of
BMP might elicit an increase in CXCR4 mRNA expression. It is also possible
that the induction caused by SKI-knockdown is already maximal. To test this,
cell lines with varying levels of SKI expression could be treated with BMP to
determine if cells with intermediate SKI knockdown showed a response. Real
time PCR could also be done for SMAD7 and WNT3 to determine if their
expression is increased in shSKI NCCIT cells upon treatment with BMP.
LEFTY1 and MAP3K7 both contained multiple copies of the BMP-specific
response element, GCCGnCGC, and the BMP/TGFβ response element,
CAGACA, suggesting they also may be up-regulated by BMP and/ or TGFβ.
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ADAMTS1 contained multiple copies of both of the BMP/TGFβ response
elements, GTCTAGAC and CAGACA. Additionally, ADAMTS1 was the only
gene queried that contained one of the TGFβ-specific response elements,
ACAGACAGACAC, further suggesting possible regulation by TGFβ.
FST (follistatin) and SPARC (secreted protein acidic and rich in cysteine)
were both down-regulated in shSKI compared to shNC NCCIT cells. Yet both of
these genes contained multiple copies of both BMP/TGFβ response elements,
and FST also contained multiple copies of the BMP-specific response element,
suggesting they also may be regulated by BMP. The presence of BMP response
elements within the promoters of these two down-regulated genes would not
support the hypothesis that decreasing SKI expression in NCCIT cells confers
increased BMP signaling and allows increased expression of BMP target genes.
FST is a negative regulator of the TGFβ superfamily, primarily activin (Ogino, et
al., 2008). It has previously been shown to be regulated by SMAD3 through a
SMAD binding element (Blount, et al., 2009), therefore, it may primarily be
regulated by activin and may not be BMP responsive. SPARC is involved in
matrix remodeling and has been implicated in cancer progression and metastasis;
however, SPARC’s role in tumorigenesis appears to be context and cell-type
dependent as it appears to act as a tumor suppressor in some tissues (Arnold
and Brekken, 2009). SPARC’s role in testicular cancer has not been studied to
date. Since SPARC did not contain the BMP-specific response element, it may
be regulated by TGFβ and not by BMP. It is also possible that there are inhibitors
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of FST and SPARC transcription present in shSKI NCCIT cells that prevent their
transcription despite the presence of SMAD binding elements within the promoter.
Finally, MMP9 was also used for the promoter analysis. According to the
microarray data, MMP9 was not differentially expressed in shSKI and shNC
NCCIT cells, and, therefore, does not appear to be responsive to SKI expression.
However, the promoter analysis shows that the MMP9 promoter does contain
both of the BMP/TGFβ response elements. It does not contain the BMP-specific
response element. Again, it is possible that this gene may be regulated by TGFβ,
which did not appear to have an effect in our system, and not by BMP. Because
two of the sequences used for this analysis have been described to be
responsive to both BMP and TGFβ induced SMADs, it is somewhat difficult to
draw a conclusion about the genes that have these two motifs in their promoters.
They could potentially be activated by TGFβ or BMP or both. The SMAD
transcription factor complex requires several binding partners to activate
transcription of target genes, and these binding partners account for some of the
specificity between TGFβ and BMP activated transcription (Massague and
Wotton, 2000). Certain DNA binding cofactors, such as FAST (forkhead activin
signal transducer), are specific to SMAD2/3-SMAD4 complexes, while others,
such as OAZ (OLF1/EBF-associated zinc finger protein), bind to the BMP
responsive SMAD complex, SMAD1/5/8-SMAD4 (Massague and Wotton, 2000).
Therefore, future studies should focus on the identification of these binding
factors to determine which are present in NCCIT cells and if potential target
genes also contain motifs for these cofactors.
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From this collection of data, a model for the acquisition of a more invasive
phenotype in testicular cancer cells is proposed that involves reduced levels of
SKI, which results in aberrant expression of both BMP-dependent and BMPindependent downstream target genes (Figure 4.1). In this model, a primitive
germ cell acquires a mutation, such as protection from antiproliferative signaling,
forming a precancerous cell. This precancerous cell then undergoes additional
transformation to gain the properties of a cancerous cell, including uncontrolled
proliferation, evasion from apoptosis, and immortalization. The acquisition of
these properties results in the formation of an intratubular germ cell neoplasia,
however further mutations are required for the ITGCN to invade the surrounding
tissue. The data presented within this text indicate that loss of function of SKI
may promote this transition to a more invasive phenotype. As shown in the
model, loss of SKI expression results in uncontrolled BMP signaling as well as
upregulation of other BMP-independent genes. Uncontrolled BMP signaling
allows increased expression of BMP target genes, some of which promote
testicular cancer metastasis. Additionally, loss of SKI expression promotes the
expression of other genes, such as CXCR4, that promote testicular cancer
metastasis. According to this model, the increased expression of CXCR4
promotes metastasis to distant sites where SDF1, the ligand for CXCR4, is
expressed; these include the lymph nodes, lung, liver, and brain. The changes in
gene expression brought on by loss of SKI result in invasion of the surrounding
lymph nodes by the cancerous cells and dissemination to distant organs.
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The microarray data presented here indicates that loss of SKI expression
enhances the expression of genes in other signaling families, such as the WNT
and MAP kinase families, thus these signaling families may also be involved in
promoting an invasive phenotype in testicular cancer cells. For example, SKI
has been shown to be a binding partner of FHL2, which can activate or repress
β-catenin, depending on cell type (Chen, et al., 2003). Therefore, decreased SKI
expression could potentially result in lack of interaction with FHL2 and lack of
repression of β-catenin in testicular cancer cells. β-catenin has previously been
correlated with an invasive phenotype in breast cancer (Niu, et al., 2009) and
colon cancer (Suzuki, et al., 2008). Further research on the interactions of these
pathways in testicular cancer cells is necessary to determine their importance in
testicular cancer metastasis.
The data presented here provide further insight into testicular cancer by
identifying SKI as a potential regulator of male germ cell tumor metastasis.
These data show that testicular cancer cells with decreased SKI expression have
a greater ability to invade and metastasize. Furthermore, the data provide
evidence that the BMP pathway plays a role in this process by further increasing
the metastatic potential of SKI-deficient testicular cancer cells. Noggin, a BMP
inhibitor, was able to reverse the effects of BMP in SKI-knockdown NCCIT cells.
This suggests that the BMP pathway may be a potential target for the
development of new therapies to treat metastatic testicular cancer. The use of
noggin, or other small molecule inhibitors of BMP, may be useful in preventing
progression of testicular cancer and warrants further research.
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In accordance with previous findings (Gilbert, et al., 2009), these data
confirm the importance of CXCR4 and SDF1 signaling partners in testicular
cancer metastasis and also, for the first time, indicate that SKI may play a role
regulating the expression of CXCR4. This implicates CXCR4 and SDF1 as
potential targets for therapies to treat testicular cancer metastasis as well. In the
current studies, AMD3100 was effective at blocking the effects of CXCR4/SDF1
signaling partners, revealing AMD3100 as a candidate for the treatment of
metastatic testicular germ cell tumors. AMD3100 is a small molecule inhibitor
that is highly specific for CXCR4 (Broxmeyer, et al., 2005; Hatse, et al., 2002)
and has been used in clinical trials as an anti-HIV drug because CXCR4 is a coreceptor used by HIV to enter T-lymphotropic cells (De Clercq, 2005; De Clercq,
2009; Hendrix, et al., 2000). In these trials, AMD3100 (Plerixafor) was very
effective in inhibiting HIV-1 and HIV-2 viral replication. While no toxicity was
observed, the main side effect in patients treated with AMD3100 was
leukocytosis, or increased white blood cells (De Clercq, 2005). The discovery of
this side effect led to clinical trials using AMD3100 as a hematopoetic stem cell
mobilizer to treat patients with non-Hodgkins lymphoma and multiple myeloma
(Stiff, et al., 2009). These clinical trials have shown that AMD3100 is safe for use
in humans, but further studies are necessary to determine the efficacy of this
drug in the treatment of testicular cancer metastasis.
Additionally, several potential targets of testicular cancer metastasis were
revealed by microarray analysis. These genes were up- or down-regulated in
SKI-deficient NCCIT cells and further studies to elucidate the interaction between
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these individual genes or signaling families and SKI will likely provide additional
targets for the development of gene therapies.
Previous studies have yielded conflicting roles for SKI in the metastatic
process (Reed et al., 2001; Le Scolan et al., 2008; Zhu et al., 2008). The studies
presented within this text are the first to implicate SKI as regulator of metastasis
in testicular cancer; this is in accordance with other studies showing that loss of
SKI function promotes invasion in some types of cancer, including lung and
breast (Le Scolan, et al., 2008; Zhu, et al., 2007). However, other studies have
shown that increased SKI expression correlates with cancer progression in
melanoma cells (Reed, et al., 2001). Taken together, these findings reveal that
metastasis is a very complex process that depends upon the various signals
present within the microenvironment of specific tissues that guide a cancerous
cell to invade the basement membrane and metastasize to distant tissues. When
compared with previous data, it appears that SKI may function to promote tumor
progression in some cell types, such as melanoma cells, but inhibit cancer
metastasis in other cell types, such as testicular cancer cells. Furthermore, the
findings on CXCR4/SDF1, taken together with previous data (Gilbert, et al.,
2009), show that not only are the factors present within the microenvironment of
the primary tumor important, but factors, such as SDF1, found in the sites of
metastasis must also be considered when attempting to develop therapies for the
treatment of malignant disease.
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Figure 4.1. Proposed mechanism for SKI’s role in testicular tumorigenesis. A
primitive male germ cell acquires a mutation, forming a precancerous cell. This
precancerous cell then undergoes transformation, gaining additional properties of a
cancerous cell, to form an ITGCN. Loss of SKI expression in ITGCN results in changes
in gene expression, both BMP-dependent and BMP-independent, that contribute to an
invasive phenotype, allowing the cancerous cells to invade the adjacent lymph nodes
and disseminate. Noggin is able to abrogate the effects of BMP in this model. BMPindependent changes in gene expression, including increased expression of CXCR4,
further contributes to the metastatic potential. CXCR4 interacts with its signaling partner
SDF1, to promote metastasis to tissues expressing SDF1. This interaction is inhibited
by AMD3100.
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SUMMARY

We have shown that SKI expression is reduced in human testicular germ
cell tumors compared to normal human testis. To our knowledge, this is the first
study showing a decrease in SKI expression in testicular cancer. Our studies
have also shown that experimentally reducing SKI in a testicular cancer cell line,
NCCIT, results in an increased ability of these cells to migrate and invade. In
parallel with this finding, forcing the overexpression of SKI in NCCIT cells
resulted in a less invasive phenotype. This data suggests that SKI may function
as an inhibitor of metastasis in testicular cancer.
Through a microarray study, we found that a large number of genes are
differentially expressed in NCCIT cells stably transfected with a shRNA vector for
SKI knockdown compared to NCCIT cells stably transfected with a negative
control shRNA vector. These differentially expressed genes are potential target
genes of SKI that may be involved in the increased invasive phenotype of SKIdeficient NCCIT cells. Furthermore, we were able to identify the presence of
BMP response elements within the promoter regions of certain genes, including
ADAMTS1, CXCR4, LEFTY1, SMAD7, and WNT3, from the microarray,
indicating that these genes are potentially upregulated by BMP signaling in SKIdeficient NCCIT cells.
We also found that TGFβ does not enhance migration in SKI-knockdown
NCCIT cells. However, BMP does enhance the migration of SKI-knockdown
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NCCIT cells, and noggin, a BMP inhibitor, blocks the effect of BMP on SKIknockdown cells. This indicates that decreased SKI expression in testicular
cancer may confer increased sensitivity to BMP-receptor driven signaling,
thereby enhancing the metastatic phenotype of these cells. Furthermore, we
found that CXCR4 expression is upregulated in SKI-knockdown cells. CXCR4,
and its signaling partner, SDF1, have previously been implicated in testicular
cancer metastasis. We found that the CXCR4/SDF1 signaling partners promoted
invasion in SKI-deficient cells but not in cells that retained a higher level of SKI
expression. This indicates that the absence of SKI is an important factor in
testicular cancer metastasis. Furthermore, our data suggest that BMP and
CXCR4/SDF1 signaling partners may be potential targets for therapies to treat
patients with metastatic testicular cancer. This is an area of research that
warrants further investigation.
The microarray data presented in this text also indicate that genes
belonging to that the MAP kinase and WNT signaling pathways are up-regulated
in SKI-deficient cells. This suggests that these pathways may be regulated at
some level by SKI expression. Certain genes in these pathways may also be
involved in promoting testicular cancer metastasis. Studying the interaction
between these pathways and the BMP pathway, and how SKI regulates their
target gene expression will likely further shed light on the mechanisms behind
male germ cell tumor metastasis and provide additional targets for testicular
cancer therapies.
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The data presented in this text identify SKI as a potential tumor
suppressor of testicular cancer and provide a mechanism by which the increased
invasive phenotype is acquired. This allows a better understanding of the
disease process involved in testicular tumorigenesis which may help with the
development of treatments for patients with disseminated disease who have a
worse prognosis. As scientific advances are made that allow the development of
therapies targeted more directly at the testicular cancer cells rather than targeting
all rapidly dividing cells, as with chemotherapy and radiation, the patients’ quality
of life will be enhanced through decreased side effects of cancer treatment.
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FUTURE DIRECTIONS

The research presented in this text provides novel information regarding a
possible mechanism by which testicular cancer cells acquire an increased ability
to invade and metastasize. However, more research is necessary to fully
understand the role that SKI plays in testicular cancer. Our data implicates SKI
as a tumor suppressor of testicular cancer. There are several mechanisms by
which tumor suppressor activity is lost in cancer cells, such as gene silencing
modifications to the promoter region, allelic loss due to chromosome instability,
and DNA sequence mutation that leads to decreased gene expression or
decreased protein activity. Additional studies could be performed to determine
the mechanism by which SKI expression is decreased in testicular germ cell
tumors compared to normal testis. This information is important because it would
further support the role of SKI as a tumor suppressor, and it would allow a better
understanding of testicular cancer progression.
Our data suggest that the BMP pathway is involved in the increased
invasive phenotype seen in SKI knockdown NCCIT cells. Further investigation
into potential BMP target genes would help in understanding exactly how this
pathway contributes to invasion in testicular cancer. The microarray analysis
provides a good starting point for looking into potential BMP target genes that
may promote metastasis of testicular cancer. Identification of these genes may
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present new targets for testicular cancer therapies. Determining the importance
of SMAD signaling in the increased invasive phenotype observed in SKI-deficient
testicular cancer cells would also provide an increased understanding of the
importance of the BMP signaling pathway. This could potentially be
accomplished using siRNA against SMADs 1, 5, and 8 or dominant negative
proteins to determine if SMAD-mediated transduction of BMP signaling is
required for the increased ability of SKI-deficient cells to migrate.
In our studies, TGFβ did not affect the invasive potential of SKI-deficient
cells. In order to better understand why TGFβ does not function to enhance
migration in SKI deficient cells, experiments could be done to identify if this lack
of response is due to inhibitors of TGFβ blocking the signal or if some component
of the TGFβ signaling pathway is not functioning properly.
Furthermore, several genes were shown to be differentially expressed by
microarray analysis in shSKI NCCIT cells compared to shNC NCCIT cells. This
microarray analysis was performed on cells that were stably transfected for SKI
knockdown or with a negative control vector; thus they do not confirm that loss of
SKI directly controls the transcription of these genes. Assays, such as lacz
transcription assays, to determine the direct interaction of SKI with the potential
target genes would provide a more detailed look at the exact pathways involved
in testicular cancer progression. Additionally, the importance of the upregulated
target genes identified by microarray analysis in testicular cancer metastasis
could be tested by using siRNA or dominant negative proteins to determine if
they are required for increased invasive potential in SKI-knockdown NCCIT cells.

114

Our experiments were performed using NCCIT cells, which are classified
as embryonal carcinomas. In reviewing the literature, it appeared that some
gene expression profiles were specific to either embryonal carcinomas or
seminomas. Our data showed that SKI was decreased in various types of
testicular germ cell tumors. Thus, it would be interesting to know if decreased
SKI expression had similar effects on seminoma cells as we saw in embryonal
carcinoma cells.
Additional experiments studying the effects of the pathways outlined in this
text in an in vivo model would be very beneficial in the clinical translation of this
research to the development of gene-targeted testicular cancer therapies. As
mentioned, the data presented here suggest that BMP and the signaling partners,
CXCR4/SDF1, promote invasion in SKI-deficient testicular cancer cells,
potentially making these molecules attractive targets for the development of new
treatments against metastatic testicular cancer. First, the efficacy and safety of
inhibitors of these pathways would need to be assessed using an in vivo model.
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CHAPTER V

METHODS
Tumors
Testicular tumors and normal human testis tissues were provided by the
Cooperative Human Tissue Network, which is funded by the National Cancer
Institute. Other investigators may have received samples from these same
tissues. Tissues were frozen in liquid nitrogen and stored at -80C until analysis.
Tumor and normal samples were analyzed for relative gene expression after
laser capture microdissection as described below.

Laser Capture Microdissection
Normal and tumor tissue specimens were embedded in Tissue-Tek OCT
(VWR, Batavia, IL) medium for frozen sectioning. Five-micrometer sections were
processed with the Arcturus HistoGene kit (Molecular Devices, Sunnyvale, CA).
Sections were briefly fixed and dehydrated in ethanol, stained with hematoxylin
and dried in xylene prior to sample capture using the Arcturus Pixcel IIe
(Molecular Devices, Sunnyvale, CA). Tissue captured from normal testes
included seminiferous tubules, but not interstitial cells. Tumor cells were isolated
avoiding stromal elements. After capture the samples were extracted for RNA
using the RNeasy Micro Kit (Qiagen, Valencia, CA). RNA quantity and integrity
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were assessed using the 2100 Bioanalyzer and the RNA Pico Kit (Agilent
Technologies, Santa Clara, CA).

Cell Culture
NCCIT cells were purchased from American Type Culture Collection
(Manassas, VA). NCCIT cells were cultured in RPMI 1640 (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA)
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). Cells were grown in a
humidified atmosphere containing 5% CO 2 at 37°C.

Materials
TGFβ, TGFβ blocking antibody, BMP4, noggin, and SDF1 were purchased
from R & D Systems (Minneapolis, MN). AMD3100 was purchased from
SigmaAldrich (St. Louis, MO).

Transient siRNA Transfections
For transfection protocols, NCCIT cells were plated in antibiotic-free RPMI
medium, and, on the day of transfection, the medium was changed to Opti-MEM
Reduced Serum Medium (Invitrogen, Carlsbad, CA) supplemented with 2% FBS.
For siRNA knockdown of SKI, three individual siRNAs specific to SKI and a nonspecific control siRNA were purchased from Invitrogen. Cells were plated in 6
well plates at 5x105 cells/well. Twenty-four hours after plating, when the cells
were approximately 60-70% confluent, the cells were transfected with one of the
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three SKI siRNAs or the non-specific control siRNA at a final concentration of 20
μM siRNA. Mock transfections, using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA), were performed to ensure that there were no adverse
consequences from the transfection procedure. Transfection efficiency was
assessed both visually and through the use of flow cytometry on cells transfected
with Block-It (Figure 5.1), a fluorescently tagged oligonucleotide, as described by
the manufacturer (Invitrogen, Carlsbad, CA). Transfection efficiencies were
routinely greater than 80%. Knockdown of SKI mRNA and protein levels were
assessed at 24, 48, and 72 hrs, using real time PCR and western blotting,
respectively.

Flow Cytometry
Cell culture medium was aspirated from cells, and the cells were washed
with PBS prior to collection via trypsinization. Cells were spun down, washed
with PBS, and resuspended in 1% paraformaldehyde/PBS solution. Ten
thousand events were analyzed using the BD FACSaria with the FITC-A laser.
To determine the transfection efficiency, the percentage of cells positive for
FITC-A was determined using BD FACSDiva software.

SKI Expression Vector Transient Transfection of NCCIT Cells
To force the expression of SKI in NCCIT cells, a SKI expression vector,
generously donated by Dr. Estella Medrano, Baylor College of Medicine, was
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to
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the manufacturer’s protocol. Briefly, NCCIT cells were plated in 6 well plates at
5x105 cells/well in medium without antibiotics. Twenty four hours after plating,
the medium was replaced with OptiMEM supplemented with 2% FBS, and the
cells were transfected with 5μg of either the SKI expression vector or the empty
vector (Invitrogen). SKI mRNA and protein levels were assessed at 24, 48, and
72 hours by Real Time PCR and western blotting, respectively.

Generation of Stably Transfected SKI-knockdown NCCIT cells
NCCIT cells were plated at 3.5X105 in antibiotic-free medium, and, on the
day of transfection, the medium was changed to Opti-MEM Reduced Serum
Medium (Invitrogen, Carlsbad, CA) supplemented with 2% FBS. Transfections
were performed on cells that had been passaged less than 5 times. Predesigned SureSilencingTM shRNA vectors specific to SKI (shSKI) and an shRNA
negative control vector (shNC) were purchased from SuperArray Bioscience
Corporation (Frederick, MD). The cells were transfected using Lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA), according to
manufacturer’s suggestions. Transfected cells were selected using 600 µg/mL
Geneticin because the shRNA vectors contained a neomycin-resistance gene.
Clones were established from single cells and were analyzed for SKI expression
via Real Time PCR and western blotting. Stably transfected NCCIT cells were
cultured in RPMI 1640, supplemented with 10% FBS and 300 µg/mL Geneticin
(Invitrogen, Carlsbad, CA). Stably transfected NCCIT cells are denoted
shNCCIT as a group. NCCIT cells stably transfected with the negative control
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A.

NCCITs- 24h 40nM Block-It

B.

C.

NCCITs- 24h 40nM mock transfection

D.

Figure 5.1. Transfection efficiency assessed by Block-It transfection. NCCIT cells
transfected with Block-It were assessed both visually and by flow cytometry for
transfection efficiency. (A) Microscopic assessment of NCCIT cells transfected with
Block-It. (B) Flow cytometry analysis of NCCIT cells transfected with Block-It. (C)
Microscopic assessment of NCCIT cells mock-transfected with lipofectamine 2000. (D)
Flow cytometry analysis of NCCIT cells mock-transfected with lipofectamine 2000.
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shRNA vector are denoted shNC NCCIT, and NCCIT cells stably transfected with
the SKI shRNA vector are denoted shSKI NCCIT. SKI knockdown was routinely
assessed via real time PCR and western blotting.

Real Time PCR
Total RNA was extracted from NCCIT cells using TRIzol (Invitrogen,
Carlsbad, CA). Relative levels of gene expression were measured by real-time
polymerase chain reaction (PCR) using Taqman probes and the 7000
Sequence Detection System (Applied Biosystems, Foster City, CA). First strand
cDNA was synthesized from 2 ng total RNA using Superscript III reverse
transcriptase (Invitrogen, Carlsbad, CA). Taqman probes for SKI, SNO, CCND2
LFT1, ADAMTS1, and CXCR4, SDF1, and 18S ribosomal RNA were purchased
from Applied Biosystems (Foster City, CA). Probes for 18S ribosomal RNA were
used as the endogenous control. Relative expression levels for SKI, SNO,
CCND2 LFT1, ADAMTS1, and CXCR4, SDF1 were calculated using the 2-Ct
method (Livak and Schmittgen, 2001). Data for the tumor samples were
normalized to the endogenous control and to the normal tissues. Data for siRNA
treated cell lines were normalized to the endogenous control and to cells
transfected with the non-specific control siRNA.

Western Blotting
Protein was extracted from NCCIT, N-TERA2/D1 (NT2/D1), HepG2,
HMEC, MCF7, T47D, A549, SbCl2, WM1366, WM9, HCT116, SK-N-AS, and SK121

N-SH cells with lysis buffer containing 50mM Tris, 150mM NaCl, and 0.1%
IGEPAL (Cobb, et al., 1997). Total protein concentration was determined by
Bradford assay. Twenty micrograms of total protein lysate were run on a 10%
SDS-PAGE gel (BioRad, Hercules, CA) and transferred to a nitrocellulose
membrane. Successful transfer of the protein was assessed by staining the blots
with Ponceau S (Sigma Aldrich, Saint Louis, MO), and then the stain was
washed off with distilled water. Membranes were blocked in a 5% powdered
milk/ PBS-Tween (0.5% Tween) (PBST) solution at room temperature for 1hr.
SKI and α-tubulin antibodies were purchased from Millipore/Upstate
(Charlottesville, VA). SMAD2, p-SMAD2, SMAD 1/5, and p-SMAD 1/5/8
antibodies were purchased from Cell Signaling Technologies (Danvers, MA).
Blots were incubated in a primary antibody (Millipore/Upstate, Charlottesville, VA)
overnight at 4°C at the following dilutions: SKI 1:2000; SMAD2 1:1000, pSMAD2 1:1000, SMAD1/5 1:1000, and p-SMAD1/5/8 1:10,000. SKI and αtubulin blots were incubated in a 1:20,000 dilution of the appropriate HRPconjugated secondary antibody (Pierce, Rockford, IL) at room temperature for
one hour. SMAD and p-SMAD blots were incubated in a 1:2000 dilution of antirabbit IgG secondary antibody (Cell Signaling Technology, Danvers, MA) at room
temperature for one hour. α-tubulin was used as a loading control for
densitometry; blots were reprobed with α-tubulin diluted at 1:10,000 at room
temperature for 10 minutes, and then secondary antibody (rabbit-anti-mouse) at
1:40,000 at room temperature for 10 minutes (personal communication with Dr.
Beverly Delidow, Marshall University). After primary and secondary antibody
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incubations, the blots were washed 4 X 5 minutes. in PBST. ECL Plus
chemiluminescent reagent (GE Healthcare) was used for detection of the
antibody as described by the manufacturer.

Cell Scrape Migration Assays
NCCIT cells were plated on Matrigel-coated cell culture plates and treated
with either siRNA or the expression vector as described. Forty-eight hours after
siRNA transfection, when the cells were ≥ 90% confluent, a 20 μL pipette tip was
used to create a scratch across the cell monolayer. shNCCIT cells were plated
and scraped in the same manner. shNCCIT cells were treated with ± TGFβ (0.1
nM), ±TGFβ blocking antibody (200 nM), or ± BMP4 (10 ng/mL), ± noggin (0.1
µg/mL). The cells were observed over a 20 hour time period, and images were
taken of three fields of view per well at 0 hour and 20 hour using a Nikon inverted
microscope (model Eclipse TS100-F) with camera attachment (Nikon Digital
Sight DS-5M). To ensure that the same fields were analyzed at 0 and 20 hours,
identifying marks were made on the bottom surface of the well. The percent
closure of the scrape was determined by measuring the mean distance between
the edges of the scrape (33 measurements per image; 99 measurements per
well) at 0 and 20 hours using Image J 1.37v Analysis Software (Wayne Rasband,
National Institutes of Health, USA, http://rsb.info.nih.gov/ij/). The percent closure
of the scrape was estimated by comparing the measurements at 20 hours to the
measurements at 0 hours. Treatments were performed in triplicate, and
experiments were repeated at least three times (n=9).
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Matrigel Invasion Assays
Forty eight hours after treatment with either siRNA or the expression
vector, NCCIT cells were removed from the 6 well plates with trypsin, washed,
and resuspended in 1 mL of serum-free Opti-MEM, and plated at 5x105 cells per
Matrigel-coated invasion chamber inserts (Falcon cell culture inserts with an 8
micron pore size PET membrane; BD Biosciences, Bedford, MA), containing a
total volume of 2 mL serum-free Opti-MEM. The inserts were held in 6-well
companion plates, which contained 2.5 mL Opti-MEM with 2% serum (BD
Biosciences, Bedford, MA). According to the manufacturer’s protocol, after a 22
hour incubation in the Matrigel invasion chambers, the cells were fixed to the
membranes and stained using the Diff-Quik Stain Set (Dade Behring, Newark,
DE), and the number of migrated cells was determined and compared to the nonspecific control siRNA-treated cells. For each well, the number of invading cells
was counted using Image J Analysis Software 1.37v in six random fields in each
of three wells per treatment, and these numbers were added to obtain the total
number of invaded cells for each sample. Each treatment was performed in
triplicate, and each experiment was performed three times.
Stably transfected shNCCIT cells were plated at 5x105 in Matrigel-coated
invasion chamber inserts in the 6-well companion plates, which contained
OptiMEM supplemented with 2% FBS ± SDF1 (25 ng/mL), ± AMD3100 (50
ng/mL).
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Microarray Gene Analysis
Stably transfected shSKI and shNC NCCIT cells were plated on Matrigelcoated 6-well plates and scraped as described for Matrigel cell scrape assays.
Seventy two hours after plating, the cells were washed with PBS and collected
using TRIzol (Invitrogen, Carlsbad, CA). Six experiments were performed with
three replicates in each experiment. The three replicates from each experiment
were pooled for the microarray analysis for a total of six shNC and six shSKI
samples. The samples were given to the Microarray Core Facility at Marshall
University, Joan C. Edwards School of Medicine in TRIzol solution. RNA
extraction, microarray analysis, and statistical analysis on the microarray data
were performed by the Microarray Core Facility at Marshall University, Joan C.
Edwards School of Medicine. Total RNA quality was determined using a Model
2100 bioanalyzer (Agilent, Santa Clara, CA). All samples had an RNA integrity
number (RIN) greater than 8. Six biological replicates were used in reference
microarray design; sample cDNA is hybridized against cDNA derived from
universal reference RNA (Stratagene/Agilent, Cedar Creek, Texas). 250 ng of
total RNA was used for labeling with the QuickAmp labeling kit (Agilent) and Cy3CTP and Cy5-CTP from Perkin Elmer as previously described (Syed and
Threadgill, 2006). ShNC or shSKI samples were labeled with Cy3-CTP, and
universal human reference RNA (Agilent, Santa Clara, CA) was labeled with
Cy5-CTP. Following purification of labeled cRNA, 825 ng of Cy3 and Cy5labeled sample were combined and hybridized on a microarray chip containing
45,016 features that represent 33,000 known and novel human genomes for 17

125

hours at 65°C in an Agilent hybridization oven. Slides containing arrays were
then washed and scanned using the Agilent DNA microarray scanner. Intensity
of microarray features was measured using Agilent Feature Extraction software
(version 9.5). Extracted data was lowess normalized.
Statistical analysis of microarray (SAM) and gene set enrichment analysis
(GSEA) (http://www.broadinstitute.org/gsea) were used to identify significant
genes and gene families that were differentially expressed in shSKI NCCIT cells
compared to shNC NCCIT cells. SAM was used to determine significant
changes in the expression of individual genes in shSKI cells compared to shNC
cells. The cutoff for differential expression was a 1.5 fold change.
The GSEA software version 2.0.4 (Subramanian, et al., 2005) from the
BROAD Institute (http://www.broadinstitute.org/gsea) was used to perform gene
set enrichment analysis. This analysis was used to compare SKI-knockdown,
shSKI NCCIT cells, to control cells, shNC NCCIT cells, to identify specific gene
sets enriched in the shSKI phenotype. The dataset queried consisted of 26,712
genes. The GSEA software is designed to filter out gene sets containing less
than 15 or more than 500 genes, which resulted in 586 gene sets to be used in
the analysis. 380 out of the 586 gene sets were enriched in the shSKI NCCIT
cells. Of these 380, 147 gene sets met the criteria of a false discovery rate (FDR)
less than 0.25, and 101 of these gene sets were significantly enriched at a
nominal p-value less than 0.05. The familywise-error rate (FWER) is a more
conservative correction that ensures that the results reported do no contain a
single false-positive gene set (Subramanian, et al., 2005); using the more
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stringent cutoff of FWER less than 0.05 resulted in only a few enriched gene
families in shSKI NCCIT cells.

Promoter Analysis
The Motif Locator tool on the MOtif Discovery (MoD) tools website
(http://159.149.109.9/modtools/) (Pavesi, et al., 2006) was used to determine if
potential target genes of SKI that were identified by microarray analysis
contained SMAD binding elements. BMP and TGFβ SMAD binding elements
were chosen via a literature search. The following SMAD binding sequences
were used: BMP elements: GTCTAGAC, (Li, et al., 2001; Zawel, et al., 1998);
CAGACA (Dennler, et al., 1998; Jonk, et al., 1998); GCCGnCGC (Kusanagi 2000,
Ishida 2000, Kim 1997, Benchabane 2003); TGFβ elements: GTCTAGAC
(Stopa 2000); AG(C/A)CAGACA (Dennler, et al., 1998; Jonk, et al., 1998);
AGACAAGGTTGT (Song, et al., 1998); ACAGACAGACAC (Wong, et al., 1999);
GCCCACCAGACAGATGGCTGAATCACAGGAGTGGCCGGCGGGACCCATGG
CCT (Kon, et al., 1999; Vindevoghel, et al., 1998);
AGACAGACAAAACCTAGACAATCACGTG
GCTGGCTGCATGCCCTGTGGCTGTTGGGC (Hua, et al., 1998);
CCTAGACAGACAA AACCTAGACAATCACGTGGCTGG (Hua, et al., 1998; Hua,
et al., 1999); GAGGAGGTAGAC AGACAGCTATGT (Lindemann, et al., 2001);
AGTATGTCTAGACTGA (Shi, et al., 1998). Two of the sequences used have
been described to be both BMP and TGFβ response sequences. In this analysis,
one substitution in the binding element sequence was allowed. The default
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minimum match percent of 85% was chosen to report motif matches, and both of
the complementary strands of the input promoter sequences were searched.
Promoter sequences were obtained from the Transcriptional Regulatory
Element Database (TRED; http://rulai.cshl.edu/cgibin/TRED/tred.cgi?process=searchPromForm) developed by Michael Zhang’s
laboratory at Cold Spring Harbor. The promoter sequences used spanned from 3000 to +300, and the following genes were searched for SMAD binding
elements: ADAMTS1, CXCR4, LEFTY1, SMAD7, SMAD6, WNT3, FST, SPARC,
and MMP9.

Statistical Analysis
Data are reported as the mean of at least three individual experiments,
and error bars represent standard error of the mean, except for the real-time
PCR analysis for which error bars represent the 95% confidence intervals. Data
were analyzed for significance with SigmaStat using a One Way Analysis of
Variance (ANOVA) with Bonferroni adjustment, T-test, or Two-Way ANOVA. For
the Two-Way ANOVA tests, all pairwise multiple comparison procedures were
assessed for significance with a Tukey test. Significance was assessed at the p
< 0.05 level.
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